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ADIPOGENESIS WITHIN A HOLLOW FIBER-BASED, THREE-
DIMENSIONAL DYNAMIC PERFUSION BIOREACTOR 
Danielle Marie Minteer, PhD 
University of Pittsburgh, 2015 
Adipose-derived stem cells (ASCs) represent a promising cell source in the field of tissue 
engineering and regenerative medicine.  Due to the wide availability and multipotent 
ability of ASCs to differentiate into tissues such as bone, cartilage, muscle, and adipose, 
ASCs may serve a wide variety of regenerative medicine applications.  Accordingly, 
ASCs have been utilized in studies addressing osteoarthritis, diabetes mellitus, heart 
disease, and soft tissue regeneration and reconstruction after mastectomy and facial 
trauma.  Traditional, static, two-dimensional cell culture of ASCs do not allow for mature 
adipocyte differentiation or long-term maintenance of adipocytes in vitro.  In order to 
study metabolic diseases, such as type II diabetes mellitus, a three-dimensional scaffold 
for in vitro adipocyte maintenance is necessary.   
In collaboration with the Bioreactor Laboratory at the McGowan Institute for 
Regenerative Medicine, our laboratory has developed the use of a hollow fiber-based 
bioreactor for three-dimensional, dynamic perfusion of ASCs and adipose tissue 
formation ex vivo, creating a stable system in which long-term culture of adipocytes is 
v 
possible, providing a model useful for potential drug discovery and tissue engineering 
applications, specifically those addressing type II diabetes mellitus.  The studies 
presented in this dissertation aim to assess metabolic activity and differentiation of ASCs 
from patients with or without type II diabetes in the bioreactor system; engineer a long-
term culture environment relevant to physiological type II diabetic and non-diabetic 
conditions ex vivo; optimize tissue growth homogeneity; enhance adipogenesis within the 
bioreactor culture with the use of a decellularized adipose extracellular matrix (ECM) 
hydrogel. 
ASCs derived from patients with type II diabetes at time of isolation were found 
to behave metabolically similar and appear architecturally comparable to those derived 
from patients without type II diabetes mellitus when differentiated and maintained as 
adipocytes in the bioreactor system.  When cultured at a physiologically relevant glucose 
level matching that of healthy patients or patients with type II diabetes, ASCs were able 
to proliferate, differentiate into adipocytes, and be maintained within the bioreactor 
system for at least one week.  A decellularized adipose ECM hydrogel was established 
and applied to the bioreactor cultures; however, due to technical challenges, no firm 
conclusions can be made. 
The microenvironment by which ASCs are surrounded is critical for cell 
differentiation and growth.  Engineering and control of such microenvironment is 
possible within the hollow fiber-based, three-dimensional, dynamic perfusion bioreactor 
culture system, proving to be a promising model for potential drug discovery and 
therapeutics.  Future directions include further evaluation of ASC differentiation and 
adipocyte metabolism within type II diabetic environments, application of established 
vi 
decellularized adipose ECM hydrogels to wound healing treatments and adipose graft 
volume retention. 
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1.0 INTRODUCTION 
1.1 ADIPOSE TISSUE 
Understanding of adipose-derived stem cell (ASC) biology is imperative to 
advance adipose-based therapies into clinical practice.  Adipose tissue is present in all 
mammalian species and some non-mammalian species, and is located in: subcutaneous 
tissues, the intraperitoneal compartment (visceral fat surrounding organs), and diffusely 
throughout the body as padding for vital structures [1].  Brown adipose tissue is highly 
functionally specialized and abundant in mammalian infants where it functions to 
maintain body heat.  This mitochondria rich brown fat is sparse in adults but can be found 
in the thorax and neck [2, 3].  This thesis will focus on white adipose tissue.  Components 
of adipose tissue involve mostly mature lipid laden adipocytes, and supporting tissue 
types: blood vessels, lymph nodes, nerves, and stromal-vascular cells. 
Adipose tissue is derived from the mesoderm, along with other migratory cells, 
including the dermis, bone and cartilage, and the circulatory system [Fig. 1].  
Adipogenesis the process of adipocyte maturation and subsequent fat tissue generation – 
involves proliferation of adipose stem cells (adipose precursor cells also known as 
preadipocytes) followed by the differentiation of the cells into mature adipocytes. 
1.1.1 Adipose Tissue Biology and Function 
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Proliferation and differentiation of ASCs are controlled via hormonal, neuronal, 
and paracrine pathways [1].  Specifically, thyroid hormones and glucocorticoids have 
been found to enhance development of adipocytes in rats [5, 6] and porcine, which are 
more comparable to human fetuses during development [7-9].  Furthermore, a 
glucocorticoid analogue, dexamethasone, is a widely accepted enhancer of preadipocyte 
recruitment and differentiation when incorporated with insulin [7].  The use of insulin 
and dexamethasone is currently being studied as a method of inducing regenerating 
adipose tissue for reconstructive surgeries at the University of Pittsburgh [10].  The main 
paracrine signal, which triggers adipocyte proliferation and differentiation, is insulin-like 
growth factor-1 (IGF-1) [7].  IGF-1 has been proven to directly increase preadipocyte 
Figure 1. Multilineage Capacity of ASCs. Derived from th emesenchymal germ line, 
adipose stem cells hold the multipotentiality to differentiate into adipocytes, 
chrondrocytes, osteoblasts, or muscle cells with the addition of proper growth factor and 
under appropriate culture conditions. Image from Minteer, et al. [4]. 
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replication and differentiation in cell lines and neutralizing IGF-1 antibodies blocks 
adipogenesis in primary cultures [11-17].    
Adipose tissue is critical for maintaining energy metabolism through storage of 
lipid, a task carried out by the mature adipocytes as a response to specific circulating 
hormones.  Adipose function is multifactorial, encompassing endocrine functions, 
glucose metabolism, and lipid metabolism.  These functional mechanisms overlap and 
interact with surrounding tissues and capillaries in addition to influencing energy 
homeostasis throughout the entire organism [18].  Over fifty biochemical products are 
secreted by adipocytes, often with factors characteristic to different fat depots.  The 
endocrine function of the adipocyte releases factors important to steroid metabolism such 
as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), monocyte chemotactic protein 
(MCP-1), plasminogen activator inhibitor-1 (PAI-1), adiponectin, resistin, leptin, and 
angiotension.  Several receptors are expressed on adipocytes for proteins involved in 
endocrine metabolism as well [19, 20]. 
Adipocytes store lipid in the form of triglycerides, which are presented to the 
adipocyte in the form of a glycerol molecule and three fatty acid chains.  Once the free 
fatty acids are transported into the adipocyte, triglycerides are reformed and stored inside 
the lipid droplet.  Hormone sensitive lipase and lipoprotein lipase regulate triglyceride 
entry, storage, and release in the adipocytes.  Knowledge of adipocyte biology and 
function, in addition to the key factors involved with endocrine, glucose, and lipid 
metabolism is necessary for the study of obesity and the several chronic diseases 
associated with adipose tissue [4]. 
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1.1.2 Obesity and Ties to Chronic Diseases 
Obesity remains an ever-growing pressing health issue in developed countries and 
is rapidly approaching epidemic status in the United States. Using body mass index 
(BMI) [Eqn. 1], “overweight” describes those with a calculated BMI between 25 and 30, 





According to the United States Centers for Disease Control and Prevention, 
approximately 35.8% of American adults and 18% of adolescents ages 6-11 years were 
obese in 2010, a steady increase since 1962 when 13% of Americans were obese [21].  
Including obesity, 69% of American adults over the age of 20 were overweight in 2011 
[21]. 
It is known that obesity can induce chronic diseases such as coronary artery 
disease, degenerative arthritis, type 2 diabetes mellitus, gall bladder disease, gout, 
hypertension, infertility, restrictive lung disease, stroke, and various types of cancers [22-
26]. Diseases influenced by obesity are characterized by abdominal, visceral fat deposits, 
causing an “apple shape” [26] (Fig. 2).  Such an effect is known as the metabolic 
syndrome.  
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Adipose tissue does function as an endocrine organ in addition to its glucose and 
lipid storage functions.  As adipocytes increase in size and a person gains weight, several 
molecular and cellular changes occur and ultimately influence whole-body metabolism.  
Horowitz et al., identified higher free fatty acid (FFA) and glycerol levels in obese 
women compared to lean women, suggesting a promotion of insulin resistance – the 
primary cause of type 2 diabetes [27, 28]. In addition to FFAs, several proinflammatory 
factors are secreted by adipose tissue, with especially strong presence in those with 
obesity.  TNF-α, IL-6, MCP-1, transforming growth factor-β (TGF-β), plasminogen 
activator inhibitor type I, tissue factor and factor VII are all elevated in obese individuals 
as compared to those with lean BMIs (< 20) [22, 29]. 
Figure 2. Metabolic Syndrome. Derived from [26]. 
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Adipose tissue is present throughout the mammalian body, whether under the skin 
to provide insulation, or surrounding organs serving as padding and protection.  While 
diseases such as type 2 diabetes and degenerative arthritis were traditionally thought to be 
diseases of the pancreas and heart, respectively, relatively recent discoveries of fat 
additionally functioning as an endocrine organ, it is clear that expansion and proliferation 
of adipose tissue indeed affects whole-body homeostasis. 
Figure 3. Endocrine Organ Functions of Adipose Tissue. Derived from Catalan et al. [29]. 
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1.1.3 Clinical Applications 
ASCs can be isolated from human adipose tissue and hold high potential to 
differentiation into mature adipocytes and other tissue types along the mesenchyme 
lineage, including chondrocytes, osteoblasts, skeletal and cardiac muscle [30-52]. 
Differentiation of ASCs into mature adipocytes has been studied in bioreactors – rotating 
wall (with and without microcarriers) and three-dimensional hollow fiber membrane-
based – as methods of long-term adipocyte culture and high throughput screening tools 
for drug discovery [53, 54]. However, one of the most promising and rapidly advancing 
clinical applications of ASCs lies in the field of clinical soft tissue regeneration and 
reconstruction [55-62]. 
1.1.4 Diabetes Mellitus 
Two types of diabetes mellitus exist: type I and type II. While this thesis focuses 
on type II diabetes mellitus rather than type I, it is important to acknowledge the 
differences between the two diseases.  Broadly, patients with type I diabetes have a lack 
of insulin as a result of an autoimmune disorder which destroys the pancreatic β-cells that 
release insulin.  Eventually, insulin production from the body is eliminated, leaving the 
adipose, liver, and muscle unable to consume glucose used to create energy.  Patients 
with type I diabetes are typically diagnosed in childhood and must take insulin, either via 
injection or pump, throughout their lifetimes in addition to testing their blood sugar 
multiple times per day.  Type I diabetic patients are encouraged to carefully balance their 
diet and exercise to aid in blood sugar level regulation. 
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Unlike type I, type II diabetes mellitus may develop at any age and accounts for 
95% of diabetic patients.  Type II diabetes is characterized by insulin resistance, a 
condition in which the body is able to produce insulin but the adipose, liver, and muscles 
are unable to absorb glucose [Fig. 4].  This results in an elevated level of blood glucose, 
signaling β-cells to increase insulin production.  Over time, the β-cells cannot maintain 
the amount of insulin necessary for glucose uptake; additionally, the insulin receptors on 
adipocytes become exhausted.  Insulin resistance is further described in section 3.1.1. of 
this thesis. Type II diabetes is preventable and reversible through lifestyle changes 
including diet and exercise regulation.  Patients diagnosed with prediabetes and type II 
diabetes are prescribed to first make the necessary lifestyle changes, then to combine with 
oral medications.  If blood sugar control is not improved, oral medication in combination 
with insulin is prescribed.  
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1.2 ADIPOSE-DERIVED STEM CELLS 
Standardized protocols to isolate adipose-derived stem cells from human adipose 
tissue are in place in many laboratories, including the Adipose Stem Cell Center at the 
University of Pittsburgh [55, 56].  Discarded adipose tissue from elective surgeries is 
Figure 4. Physiology of insulin resistance in type II diabetes [63].  In healthy patients, insulin 
secretion from the pancreas reduces glucose output by the liver and increases glucose uptake by 
the skeletal muscle and adipose tissue.  Less insulin secretion reduces insulin signaling in target 
tissues, leading to an increase in fatty acid circulation and elevated blood glucose levels.   
1.2.1 ASC Isolation and Culture Conditions 
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collected from the operating room.  Whole fat tissue is chopped by hand with sterile 
scissors until finely minced.  The mechanical processing step is not necessary for 
lipoaspirate, which is already in particulate form following harvest.  To remove the 
fibrous, collagen content of the tissue, a collagenase solution is added to the minced fat 
and shaken at 37 °C until a fatty supernatant is clearly visible within the solution.  
Typically, after 25-30 minutes, a fatty layer rises and the tissue-collagenase solution 
should be centrifuged for 10 minutes at 1000 rpm at 4 °C.  Next, the supernatant/fatty 
layer is aspirated and the pellet resuspended in an erythrocyte lysing buffer to remove any 
red blood cells.  Filtering and washing steps are performed with centrifugation at 1000 
rpm, 4 °C, for 10 minutes.  The resultant SVF pellet is can be re-suspended, cultured, and 
assessed for functional capacity [62].  ASCs will adhere to the surface of an untreated 
flask after approximately 6 hours incubation at 37 °C and 5% CO2.  Once ASCs have 
adhered to the culture flask surface, non-adherent populations are washed away with 
sterile phosphate buffered solution and fresh culture media added to the flask.  Essential 
points in the ASC isolation protocol are highlighted in Figure 5. 
A commonly used ASC expansion media consists of a DMEM and 
DMEM/F12media combination, with 10% serum, some form of antibiotic (typically 
penicillin/streptomyocin), and typically a miniscule amount of dexamethasone, which 
prevents any differentiation into another mesenchymal lineage, such as osteoblasts. 
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1.2.2 Differentiation Potential of ASCs 
“Pre-adipocytes” were first described over 40 years ago, first in rat models [64, 65] 
and then isolated from human tissues in 1976 by Dardick et al., [66].  Isolated pre-
adipocytes were used to study adipocyte biology in vitro and different anatomic locations 
and adipose depots became known to express different biological characteristics such as 
adipocyte size and lipolytic potential [65].  In 2001, Zuk et al. first published the 
Figure 5. The SVF and ASC isolation process as described by Rubin and Marra [49].  
First, whole adipose tissue or lipoaspirate is finely minced and enzyme digested in at 37 °C.  
Red blood cells are lysed and the suspension is filtered.  Following centrifugation, the pellet 
is considered the stromal vascular fraction.  Once plated and cultured on a tissue culture flask 
at 37 °C  and 5% CO2 for 6-8 hours, the mesenchymal ASCs are obtained.  Adapted with 
permissions from Rubin and Marra [56]. 
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plasticity of differentiation of pre-adipocytes [30].  The stem cell features of 
“preadipocytes” became accepted and the term “adipose-derived stem cells” was given to 
encompass their characteristics of self-renewal, asymmetric division, and multipotency. 
Over the past decade, several researchers have studied ASCs’ ability to differentiate both 
in vitro and in vivo.  While ASCs typically proliferate quite well in culture, high 
concentrations of growth factors are necessary to induce lineage specific differentiation.  
Differentiation of ASCs to other mesenchymal phenotypes has been well established both 
in vitro and in vivo [30-43, 53-58, 67-69] while differentiation of ASCs to cell lines of the 
ectodermal [32, 39, 44-46] and endodermal [47-51] germ layers has been studied, 
evidence often putative to show successful achievement of the desired phenotype. 
It is imperative to note that both the SVF and ASC populations derived from 
tissues are not pure populations; numerous cell types exist within the SVF and ASC 
populations, confirmed by cell surface markers identified by flow cytometry [61, 68].  
Zimmerlin et al. identified several similar cell surface markers in ASCs compared to bone 
marrow-derived stem cells and are described in Table 1.  Li, et al. described four 
subpopulations of ASCs within the final stem cell pool cultured in vitro [68].  The first 
subpopulation is a CD31+/34- population classified as “mature endothelial,” with the 
endothelial marker of CD31 but lacking the progenitor marker of CD34.  The second 
subpopulation is classified as “endothelial stem,” and both CD31+/34+.  A third 
subpopulation consisted of CD34+/31- and is classified as the “adipose stem cell” group.  
The final subpopulation, as described by Li, et al., represents a “pericyte group” and 
isCD146+/90+/31-/34-.  These cells reside adjacent to the endothelial cells, as 
demonstrated by immunostaining [37].  As with bone marrow-derived stem cells, ASCs 
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do not express MHC-II and do inhibit proliferation of activated peripheral blood 
mononuclear cells, suggesting a role for modulating the immune system in inflammatory 
disorders or allogeneic transplantation [67]. 
The immunomodulatory potential of mesenchymal stem cells (MSCs), 
particularly, ASCs, make them an attractive tool in cell therapy protocols for the 
treatment of inflammatory-related diseases such as rheumatoid arthritis or multiple 
sclerosis [70-72].  Specifically, MSCs possess the ability to suppress T cell responses and 
modify dendritic cell differentiation, maturation and function; MSCs are not inherently 
immunogenic and do not induce alloreactivity to T cells and freshly isolated natural kill 
(NK) cells [73].  A 2014 study further confirmed ASC T helper (Th) type Th1/Th2 
cytokine profiles as well as their ability to inhibit lymphocyte proliferation in culture.  
Sempere et al. found a heterogeneous cytokine production profile, heterogeneous 
capabilities to produce lymphocytes and NK cells [70].   
Studies identifying SVF and ASCs as heterogeneous populations emphasize the 
importance of defining subpopulation potential.  Planat-Bénard, et al. cultured the SVF 
from human adipose tissue in vitro and determined that a population spontaneously 
differentiated into cardiomyocytes without the addition of growth factor [31].  
Zimmerlin, et al., identified several similar cell surface markers in ASCs (the cultured 
population) compared to bone marrow-derived stem cells (BMSCs) and are described in 
Table 1 [4, 62].  Cardiomyocytes were identified by morphology and confirmed by 
expression of cardiac-specific markers, immunohistochemistry straining, and 
ultrastructural analysis.  The need for cardiomyocyte differentiation without the use of 
controversial, difficult to culture embryonic stem cells is of high demand in the field of 
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cardiac regeneration.  The Planat-Benard et al. group later utilized adipose-derived stem 
cells in the form of a “cell sheet” in the rat [74] and non-human primate [75] chronic 
myocardial infarction model.  The finding is certainly valuable in the field of cardiac 
engineering and identifying a source of cardiomyocyte progenitors has been of great 
interest for therapeutic models targeted towards myocardial infarction. 
Table 1. Surface Marker Characterization of ASCs and BMSCs. 
Restated from Minteer et al. [4], where ASCs were freshly isolated and examined via 
flow cytometry [62]. 
Adipose-Derived Stem Cells Bone Marrow Stem Cells 
Negative 
CD38, CD45, CD106, HLA-DR, 
DP, DQ (MHC Class II), CD80, 
CD86, CD40, and CD40L 
(CD154). 
CD34, CD38, CD45 and fox 
antigens involved in 
immunological signal 
transduction such as HLA-
DR, DP, DQ (MHC Class 
II), CD80, CD86, CD40, 
and CD40L (CD154). 
Positive 
CD13, CD29, CD34, CD44, 
CD73, CD90, CD105, CD166, 
MHC Class I, HLA-ABC. 
CD13, CD29, CD44, CD73, 
CD90, CD105, CD166, 
MHC Class I, HLA-ABC. 
1.2.3 Challenges in ASC Culture 
A major challenge of utilizing ASCs derived from human tissue lies in the 
variation between specimens harvested from different patients and also different 
subcutaneous depots in the same patient.  Schipper et al. studied ASCs from five different 
subcutaneous adipose depots in 12 female patients (similar BMI), split into three age 
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ranges: 25-30, 40-45, and 55-60 years [52].  The five subcutaneous depots studied were 
upper arm, medial thigh, trochanteric, superficial abdominal, and deep abdominal.  The 
goal was to determine a group of cells most suitable for soft tissue reconstruction 
applications.  It was found that ASCs from younger patients proliferated at a faster rate 
than the ASCs isolated from older patients and apoptosis of ASCs was found to be lowest 
in younger patients and from the superficial abdominal depot in all age ranges.  While 
lipolysis varied in age and depot, the cells from the patients in the youngest age range had 
the highest activity in each adipose depot.  The functional superiority of ASCs from 
younger patients and/or the superficial abdominal depot may have implications for tissue 
engineering applications. 
The role of gender and anatomical region on osteogenic differentiation of ASCs 
has also been studied in vitro [69].  ASCs isolated from the superficial and deep adipose 
layers of male and female patients were exposed to osteogenic differentiation medium for 
time points of 1, 2, and 4 weeks.  Through alkaline phosphatase, alizarin red, and 
Masson’s Trichrome staining, as well as ELISA and Western blot analysis, the group was 
able to determine that no significant difference in the amount of osteogenic 
differentiation exists in both fat depots from females, while the superficial depot in the 
male provided ASCs that differentiated sooner and more efficiently than ASCs from the 
deep fat depots.  Furthermore, it was established that male ASCs differentiated more 
effectively into osteoblasts than female ASCs from all depots. 
For large-scale culture experiments specifically examining adipogenesis, the 
murine 3T3-L1 cell line can be a useful model when consistency of cells is needed 
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overtime.  These cells can be easily differentiated into adipocytes when stimulated with 
the proper conditions in vitro [67]. 
1.2.4 Pre-Clinical Models 
There are several animal models that are useful for the examination of adipose 
tissue engineering, and the mouse model has been the most widely examined [43, 44-47, 
51].  The effects of species, strain, gender, implant configuration and implant location are 
all essential parameters when examining mesenchymal stem cells in preclinical studies 
[62].  When examining stem cell survival and behavior in small animals, there are two 
logical models for the researcher.  One model is to utilize a nude, or athymic, animal, 
which will not reject human tissue or cells.  The athymic nude mouse is maintained as an 
outbred specific, originated from the NIH.  It lacks a thymus, is unable to produce T cells 
and is, therefore, immunodeficient.  Without the thymus, athymic nude mice have a much 
reduced lymphocyte population composed almost entirely of B-cells and a greatly 
increased susceptibility to infection [76-79].  Stimuli are still capable of activating the 
macrophage of thymic deficient mice; mononuclear cells are present and macrophage 
function is enhanced [80, 81].  This is ideal for those examining the clinically relevant 
human cell, tumor biology and xenograft research.  The second model involves injecting 
autogenous or syngeneic cells derived from the mouse.  For example, this would entail 
isolating a population of cells from the strain of inbred mice, and injecting those cells into 
the mouse model.  There are advantages and disadvantages of both of these approaches.  
Either option could result in a shortage of cells, depending on the mesenchymal stem cell 
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source.  A second disadvantage of the nude mouse model is that it will not result in a 
similar response to that of the human response. 
After the animals have been injected with stem cells, it can be challenging to 
identify and characterize the implanted cells.  One method of quantification involves 
using pre-labeled cells.  Cells can be labeled with cell membrane dyes such as PKH26 or 
using viral technology, such as green fluorescent protein (GFP) labels using lentiviral 
vectors.  The expression of cell membrane dyes decreases with each cell doubling, and 
the dye could possibly leach into other cells. GFP-labeled cells, however, tend to remain 
stable throughout the lifetime of the animal.  Finally, one can utilize immunostaining to 
identify the implanted cells.  A challenge with immunostaining, however, is the potential 
for cross-reactivity of antibodies with both human and animal tissue. 
1.3 BIOREACTORS 
Traditionally, bioreactors are utilized for various biochemical engineering 
applications and bioprocesses.  For example, a bioreactor to support microbial growth 
using a vessel to convert nutrients that organisms extract from the culture media into 
biological compounds.  Current topics of investigation include quantifying energy 
production and monitoring biosynthesis and product formation throughout 
experimentation. 
In 2006, Bilodeau and Mantovani defined bioreactors in tissue engineering and 
regenerative medicine as “any apparatus that attempts to mimic and reproduce 
1.3.1  Bioreactor Trends in Tissue Engineering 
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physiological conditions to maintain and encourage cell culture for tissue regeneration” 
[82].  Through recent advances within the biomedical arena, bioreactors have been 
applied to create a cell culture environment more physiologically representative than 2-
dimensional cell culture [54, 82-100].  Traditional cell culture typically involves plating 
the isolated cells on a flat surface, usually a Petri dish or tissue culture treated flasks, and 
supplementing the cells with a nutrient media.  Cells are stored, statically, at37 °C with 
exposure to 5% carbon dioxide. 
Opposed to 2-dimensional static culture, cells can be differentiated into 3-
dimensional tissue structures within a bioreactor, making possible several potential 
applications including microgravity environments [91, 92] and long-term tissue culture 
[54] attributes that are further described in this thesis and used as a defining
characteristics of a “bioreactor.” Several classes of bioreactors exist in the biomedical 
field, and applications vary with bioreactor classification, as bioreactor design influences 
tissue formation and behavior.  The “E-Cube System” from Corning may allow the 
culture to be explanted and incorporated into an in vivo model (Fig. 6C).  Dynamic 
perfusion bioreactors deliver continuous, dynamic perfusion of nutrients and gas 
exchange to the tissue growing within [87].  The dynamic perfusion bioreactor has been 
used to culture various tissue types, including cartilage [94] bone [95], adipose [54], and 
neuronal [83].   
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Cells in dynamic perfusion bioreactor cultures grow and attach to an 
interconnected network of porous, polymeric fibers inside the bioreactor chamber while 
the nutrient medium is continuously recirculated throughout the system [93].  In addition 
to cell culture, the dynamic perfusion bioreactor has served as a “bridge to transplant” for 
patients on the ever-growing transplant lists. Irgang et al developed an extracorpeal 
bioartificial liver support system in a 3-dimensional, hollow, fiber-based bioreactor to 
successfully treat patients with porcine liver cells prior to liver transplantation with no 
known negative immunologic responses or infection [96]. Dynamic perfusion bioreactor 
Figure 6. Common bioreactors for tissue engineering. A) Spinner flask diagram [101], 
B) polyethersulfone hollow fiber membranes [102], C) E-cube system by Corning [103], 
D) rotating wall vessel [104].
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studies in the same German bioreactor laboratory are ongoing with Miki et al. and 
include differentiating human embryonic stem cells into human hepatocytes within the 3-
dimensional culture system, further addressing drug discovery, toxicology studies, and 
bioartificial liver support systems [97]. 
In 2008, Brayfield et al. reported application of a hollow fiber scaffold towards 
directing neurite outgrowth and neuronal cell networking in vitro [84].  Polyethersulfone 
(PES) microporous hollow fibers were albated with krypton fluoride (KrF) excimer laser 
to generate specifically designed channels for directing neurite outgrowth into the 
luminal compartments of the fibers.  Laser modification to PES membranes resulted in 
increased hydrophobicity and laminin adsorption on the surface compared with the 
unmodified PES surface, further correlating to PC12 cell adhesion.  PC12 cells 
differentiated on the laser-created channels, providing a spontaneous cell process growth 
into the channels of the scaffold wall while preventing entrance of cell bodies.  These 
results suggest the laser-modified PES fibers could be used in combination with perfusion 
and oxygenation hollow fiber membrane sets to construct a 3D bioreactor for controlling 
and studying in vitro neuronal networking [84].  
For other tissue culture models, a more simplistic spinner flask model is 
commonly used. The spinner flask bioreactor consists of a bottle of culture medium, well 
mixed by a magnetic stir bar, with the tissue matrix fixed to needles attached to the top 
lid or floating in the media suspension [93].  Bioreactors with rotating wall vessels 
involve angular movement of polymeric cylinders within an encasing while the tissue is 
positioned between the cylinders on biomaterial scaffolds.  Alternatively, rotating 
bioreactors involve movement or rotation of the entire bioreactor system as a whole. 
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Rotation of the system introduces continuous free fall to the culture, improving nutrient 
transport to the tissues as well as a more homogenous tissue growth [93]. 
The requirements for engineering a rotating bioreactor vary based on the tissue to 
be studied and clinical need to be addressed. Korossis et al stated that, “the overall goal is 
to have systems that reliably and reproducibly form, store, and deliver functional tissues 
that can sustain function in vivo.”  Biomolecularly, variables include metabolic activity 
of the tissue, biochemical growth factors, and oxygenation to the tissue matrix.  
Regarding bioprocesses, considerations of a rotating bioreactor include angular velocity, 
angle of rotation, removal of cellular waste products, time points, and which phase of 
culture the bioreactor should rotate.  Each consideration is a function of the dimensions 
of the tissue, including concentration of cells at initial inoculation; complexity and, 
therefore, the physiological environment required of the tissue; and stages of cellular 
differentiation and maintenance.  In addition, the consideration of continuous perfusion to 
the system contributes complexity to the system, particularly when scale-up is in question 
[93].  Bioreactors are also commonly utilized in tissue engineering to mechanically 
precondition tissue and biomedical devices before implanting in vivo [98-100]. 
1.3.2 Bioreactors in Diabetes Mellitus Applications 
While exact mechanisms of diabetes mellitus are still under speculation, it is 
widely accepted that both type I and type II diabetes are characterized by the transport of 
glucose from blood to cells, a consequence of β-cell failure in the pancreas [105].  
Simply, β-cell apoptosis in type I diabetes mellitus is activated, in part, by cytokines 
produced by invading immune cells.  Type I diabetic patients closely monitor insulin 
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levels throughout their entire lifetime and, while an inconvenience, glucose levels in type 
I diabetic patients are relatively manageable.  Alternatively, β-cell death in patients can 
result with type II diabetes mellitus occurs more gradually.  β-cell dysfunction of type II 
diabetic patients results from elevated levels of glucose and free-fatty acids (FFAs) and, 
along with other factors, eventually leads to β-cell apoptosis [105]. 
Patients diagnosed with type II diabetes mellitus are instructed to monitor their 
blood glucose levels through blood glucose monitoring devices in combination with 
lifestyle adjustments and management.  If the diabetic symptoms progress, oral 
medication, and possibly insulin, is prescribed.  Type II diabetes is often associated with 
cardiovascular disease risk factors, including elevated blood pressure and cholesterol 
levels, gall bladder disease, degenerative arthritis, gout, infertility, restrictive lung 
disease, stroke, and various types of cancers [24-27]. 
According to the Centers for Disease Control and Prevention, diabetes mellitus 
affected 29 million, or 9.3% of, United States residents in 2012, a national burden of 
$245 billion [106].  As diabetic diagnoses and associated symptoms continue to escalate 
in industrialized countries, further understanding of the disease becomes more significant.  
One of the first known groups to establish a microgravity environment for cell culturing 
purposes was a team within the National Aeronautics and Space Administration (NASA) 
Johnson Space Center in the late 1980’s.  The NASA team removed almost all shear 
forces traditionally applied to a cell culture system, forcing the cells to assemble in 
suspension and form a three-dimensional tissue matrix [107].  VivoRx, a Santa Monica-
based pharmaceutical company, licensed the rotating vessel bioreactor technology in the 
early 1990’s for therapeutic and diagnostic commercial applications.  Due to short supply 
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of pancreas cadavers, VivoRx intended to use the device to grow sufficient volumes of 
human islet cells as an answer to the expanding diabetic market.  In 1997, VivoRx 
reported commencement of FDA-approved Phase I/II clinical trials [108].  The license 
was later retracted by NASA and Synthecon currently owns licensing rights.  The rotating 
wall vessel (RWV) is commercially available and widely accepted as a three-dimensional 
culture condition option.  In a 2012 update, Barzegari et al., specifically outline 
microgravity tissue engineering and diabetes applications [109].  The reviewers explain 
that microgravity has been proven to enhance survival and proliferation of beta islet cells 
in addition to reducing immunogenicity [110-112].  
The RWV system has since provided inspiration to many three-dimensional 
bioreactor culture models useful in diabetes mellitus applications [112-116].  A 
horizontally-rotating high aspect ratio vessel is described by Murray et al. to improve 
structural and functional viability of isolated human islet cells within the microgravity 
environment [113].   Throughout a ten-day period, structural integrity and glucose-
stimulated insulin release were maintained in islets cultured within the system, compared 
to islets cultured under conventional standards.  Islets cultured conventionally were 
reported to exhibit progressive fragmentation and a rapid loss of secretory function.  
Furthermore, the authors noted that islets cultured within the microgravity environment 
were able to re-aggregate and exhibit enhanced secretory capacity [113].   
Samuelson and Gerber [114] apply the microgravity concept to a pancreatic 
progenitor cell population in a three-dimensional culture system.  The researchers 
developed a RWV bioreactor consisting of a pivoting platform to rotate around a fixed 
point, with motor-controlled rotation power and revolution speed.  Cell cultures were 
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contained in transparent fluoroethylene propylene closed culture bags with Cytodex-3 
microcarrier beads along with beta-TC-6 cell lines added in culture media suspensions.  
Bags were continuously rotated on the bioreactor platform and nutrient media was 
manually changed two times per week.  Cultures were maintained for 5 and 12 days 
within the RWV bioreactor and the pancreatic cell line proliferated robustly with 
enhanced transcriptional signaling and improved translation of the insulin gene.   The 
authors propose a future for the novel device in the potential cell-based therapy for 
treatment of diabetes [114].  
Tanaka et al., more recently describe optimization of a cell culture technology 
using a simulated microgravity generator to induce development of a large amount of 
pancreatic beta-cell spheroids [115].  Via the described methods, 100 spheroids of 250-
micrometer diameters per 1 milliliter of culture media are produced.  The spheroids were 
transplanted in vivo into the portal vein of streptozotocin-induced diabetic mice and 
lowered glycemic levels were observed over 28 days.  The spheroids cultured in the 
microgravity bioreactor expressed several β-cell signature genes at higher levels than the 
levels found in the cells cultured in a standard 2D culture dish.  Transplantation of the 
spheroids into the portal vein of the streptozotocin-induced diabetic mice amerliorated 
hyperglycemia, whereas the 2D cultured cells did not have a significant effect [115].  
In addition to the RWV bioreactor, hollow fiber bioreactors [117, 118] have been 
developed to address type I diabetes mellitus therapeutics as well as spinner flask 
bioreactors with islet cells in suspension [119].   Hoesli et al., developed a mammalian 
cell immobilization in alginate-filled hollow fiber bioreactors for large-scale batches 
[117].  The model was successfully applied to primary neonatal pancreatic porcine cell 
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culture for 10 days.  The authors describe potential future study directions that include 
donor-scale immobilized mammalian cell culture with cell recovery, such as in vitro 
culture of islet-like clusters for use in islet transplantation [117].   
Due to the vast mechanical and pathological difference in the cause of type I 
versus type II diabetes mellitus, it is only logical for therapy and treatment of the two 
diseases to also vary significantly.  Since type II diabetes mellitus is typically tied to 
other health complications, many tissue engineers have taken to bioreactor technologies 
to address the diseases’ symptoms and characteristics, including diabetic retinopathy 
[120] and foot wound ulcers [121, 122].  Dutt et al., apply the horizontally rotating
bioreactor developed by NASA to establish a co-culture of human retinal cells and 
bovine endothelial cells incorporated onto laminin-coated Cytodex-3 microcarrier beads 
over 36 days [120].   The bioreactor was reported to accelerate capillary formation as 
well as differentiation of retinal precursor cells.   With such neovascularization modeling, 
the bioreactor system could provide an ideal three-dimensional platform to study retinal 
diseases, including diabetic retinopathy [120].   
One common characteristic to diabetes mellitus is the metabolic syndrome, which 
is influenced by obesity and characterized by abdominal, visceral adipose deposits, 
causing an “apple shape” [26].  Adipose plays a dominant role in diabetes mellitus as 
adipocytes contain FFAs and release hormones that even further increase FFAs, high 
levels of which are toxic to β-cells and lead to dysfunction.  As adipocytes increase in 
size and mass, macrophages accumulate and cause inflammation, increasing a patient’s 
risk to develop diabetes [20].   In muscle and adipose tissues, glucose transporter 4 
(GLUT4) is responsible for the transportation of glucose from intracellular stores to the 
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plasma membrane [123].  Therefore, metabolism and blood glucose monitoring are 
widely studied in applications addressing type II diabetes mellitus [124]. 
Two particular studies observe the stomach as a bioreactor [123, 124].  Kanner 
and Lapidot simulated possible reactions that could occur in the acidic pH environment 
of the stomach that could affect lipid peroxidation [125].  The study hypothesized that 
prevention of overall lipid peroxidation in the stomach could have an important impact 
on health and may aid in explaining health benefits of diets rich in polyphenolic 
antioxidants.  Acidic pH of gastric fluid amplified lipid peroxidation and incubation of 
heated muscle tissue in simulated gastric fluid enhanced hydroperoxide accumulation by 
6-fold over 2 hours.  The authors suggested that human gastric fluid might be an excellent
medium for enhancing the oxidation of lipids and other dietary constituents [125].  
Similarly, Gorelik et al., evaluated hydroperoxide and malondialdehyde levels of the 
stomach during and after digestion in rats [126].   Rats were fed either A) red turkey meat 
cutlets or B) red turkey meat cutlets and red wine concentrate and stomachs were 
analyzed 90 minutes after feeding.    The study tested the hypothesis that the stomach can 
act as a bioreactor, in which lipid peroxidation of partially oxidized food (such as red 
meat and red wine) could occur, resulting in accumulation of lipid peroxidation products.  
Results indicated that stomach hydroperoxide and malondialdehyde concentrations both 
dropped substantially 90 minutes after meals and the addition of red wine polyphenols 
enhanced hydroperoxide reduction by 3-fold.  The authors conclude that addition of 
antioxidants such as red wine polyphenols to meals may reduce potentially harmful 
effects of oxidized fats in foods [126].  
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Other additional work has been conducted on lifestyle management factors for 
patients with diabetes [127, 128].  Sook et al., optimized a stable cell culture condition 
within a packed-bed bioreactor for production of tagatose, a novel bulk sweetener which 
tastes similar to sucrose with potential to be used as a low-calorie sweetener in foods, 
beverages, health foods, and dietary supplements [127].  Ho et al., developed a long-life 
capillary enzyme bioreactor for highly sensitive determination of blood glucose 
concentration [128].  While the aforementioned studies focus on lifestyle, the presented 
thesis addresses adipose behavior and adipose function in culture and how it relates to 
diseases such as type II diabetes mellitus. 
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Table 2.  Bioreactor Technologies Addressing Diabetes Mellitus [129]. 
Authors Bioreactor Type Application 
Chick et al., 1980 
Microgravity rotating 
wall 
Pancreatic cell culture 
Reach et al., 1990 Hollow fiber membrane 
Kinetic modeling, vascular bioartificial 
pancreas 
Todisco et al., 1995 Hollow fiber membrane Controlled insulin release 
John Wong, 1997 
NASA microgravity 
rotating wall 
Transplantation of encapsulated islet 
cells, VivoRx 
Naughton et al., 1997 Closed system 
Dermagraft characterization; diabetic 
wound ulcers 
Kanner et al., 2001 Stomach model 





Dermagraft scale-up; diabetic wound 
ulcers 
Rutsky et al., 2002 Microgravity 
Immunogenicity and functional testing of 
pancreatic islets 
Dutt et al., 2003 
NASA horizontal 
rotating 
3D co-culture of human retinal cells with 
bovine aortic endothelial cells for diabetic 
retinopathy 
Murray et al., 2005 
Rotational cell culture 
system 
Glucose responsiveness of human islets 
Sook et al., 2005 Packed-bed Tagatose production 
Chawla et al., 2006 Suspension 
Production of islet-like structures from 
neonatal porcine pancreatic tissue 
Stepkowski et al., 
2006 
Microgravity 
Tolerance of dendritic cells to pancreatic 
islet allografts depleted of donor dendritic 
cells 
Ho et al., 2007 Capillary enzyme Blood glucose determination 
Papas et al., 2007 Stirred microchamber 
Pancreatic islets, oxygen consumption 
rate measurements 
Gorelik et al., 2008 Stomach model Food oxidation/antioxidation 
Hoeli et al., 2009 
Alginate-filled hollow 
fiber 
Large-scale production cellular therapies 
Lu et al., 2011 Hollow fiber 3D culture of hepatocytes 
Samuelson & Gerber, 
2013 
Rotating wall vessel 
Function and growth testing of a 
pancreatic cell line 




Pancreatic beta-cell spheroid generation 
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1.4  LIMITATIONS OF PREVIOUS RESEARCH AND SUMMARY 
1.4.1 Limitations in Adipocyte Culture Methods 
Traditionally, primary ASCs are cultured on flat two-dimensional tissue culture-
treated flasks; although, once differentiation into adipocytes is induced, the cells undergo 
morphological changes and float on top of the medium due to their high lipid content.  
Adipocytes floating on top of the culture medium leads to the adipocyte clumping 
together, rendering them unable to reach equal and sufficient access to nutrient medium.  
As a result, the majority of adipocytes undergo cell lysis within 72 hours.  To overcome 
this challenge, in 1986, Sugihara et al. first laid the groundwork of culturing adipocytes 
using a ceiling culture method [130].  Sugihara et al. isolated human adipocytes, plated 
on tissue culture flasks, and filled the flasks entirely with culture medium, ensuring an 
air-free environment.  The culture flasks were turned upside side so that the cells would 
float to the top and adhere to the top inner surface (ceiling surface) of the flasks.  When 
the cells firmly attached, the flasks were then turned so that the cells were on the bottom 
inner surface and could be easily observed.  After 7-10 days in culture, the cells became 
multi-ocular (opposed to the uniocular lipid droplet defining mature white adipocytes), 
indicating de-differentiation [130].  Using the work discovered by Sugihara et al., other 
teams have studied adipocytes in modified ceiling cultures involving a floating glass 
surface [131] and adipocyte function [132]. 
In order to differentiate ASCs to adipocytes and maintain for time periods of days 
to weeks, a three-dimensional scaffold is necessary.  Groups have studied the 
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differentiation of ASCs into adipocytes in natural [90, 133-135] and synthetic [136-138] 
three-dimensional scaffolds, while few have studied the capacity of cell lines to 
differentiate into adipocytes in three-dimensional scaffolds [139-142].   Additionally, 
several studies have utilized the 3D scaffold culture for successful ASC differentiation 
into osteoblast and chondrocyte lineages [143-151].  The studies are described further in 
Table 3.   While the above work has built the foundations on adipocyte culture, the next 
step towards fully understanding adipose tissue’s role in diseases such as obesity and type 
II diabetes mellitus is to apply the three-dimensional cultures to study adipocyte behavior 
and functionality in diabetic environments.  
Table 3.Three-dimensional scaffolds for adipose tissue engineering. 
Reference Cell Differentiation Scaffold Material 
Flynn 2007 Primary ASCs Adipogenic 
Decellularized human 
placenta and crosslinked 
hyaluron 
Halbleib 2002 Primary ASCs Adipogenic Hyaluronic acid 
Mauney 2007 Primary ASCs Adipogenic Silk fibroin 






Patrick 1999 Primary ASCs Adipogenic 
Poly (lactic-co-glycolic) 
acid (PLGA) 
Kral 1998 Primary ASCs Adipogenic 
Fluortex-expanded 
polytetrafluoroethylene 
Rubin 2007 Primary ASCs Adipogenic Collagenous microbeads 
Green 1974 3T3-L1 Adipogenic Methyl cellulose 
Green 1975 3T3-L1 Adipogenic Methyl cellulose 






Utilizing three-dimensional perfusion culture systems surpasses the limitations of 
two-dimensional culture through the advantages of providing uniform nutrient and gas 
exchange with more physiological gradients and integral oxygenation.  Additionally, 
bioreactor designs based on interwoven sets of semi-permeable hollow fibers employ a 
bicarbonate buffer system and CO2 gas exchange to enable pH regulation to the entire 
cell compartment volume with negligible shear stresses.  Such three-dimensional 
perfusion culture bioreactors offer a better environment for sustained long-term cultures 
of cell types without requiring mechanical stimuli [54]. 
Figure 7 depicts adipose tissue generated within a hollow fiber-based three-
dimensional perfusion bioreactor (Fig. 7B and D) compared to ASCs differentiated to the 
adipocyte lineage in a two-dimensional tissue culture flask (Fig. 7A and C).  The Oil Red 
O in Figure 7A and B represents lipid and is much more noticeable and defined in 
samples taken from the three-dimensional perfusion bioreactor than from the ASCs 
differentiated in two-dimensional culture.  Similarly, the H&E in Figure 7C and D 
highlights oil architecture from the two-dimensional differentiated cells but mature 
adipose tissue from the samples extracted from the bioreactor.  
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1.4.2 Challenges in Isolating Tissue from Diabetic Adult Donors 
To better understand high impact diseases such as type II diabetes and obesity, the 
study of adipose tissue, metabolism, and the correlations to whole-body homeostasis and 
insulin/glucose production are necessary.  However, obtaining and culturing adipose 
tissue from patients with type II diabetes mellitus is a challenge on many accounts.  
Figure 7. Oil Red O and H&E. A). Oil Red O stain of ASCs cultured in two dimensions on 
traditional tissue culture flasks, B) Oil Red O stain of extracted adipose tissue cultured within a 
three-dimensional dynamic perfusion bioreactor; C) H&E of ASCs cultured in two dimensions on 
traditional tissue culture flasks, D) H&E of extracted adipose tissue cultured within a three-
dimensional dynamic perfusion bioreactor. 
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Obese patients with type II diabetes provide high risks to undergo cosmetic surgery, and 
other surgical procedures, such as a gastric bypass, do not yield adequate amounts of 
adipose tissue to harvest and culture ASCs in high numbers.   
While our laboratory has previously modeled insulin resistance in the adipose 
bioreactor over a time period of four hours via introduction of tumor necrosis factor-α 
(TNF-α) to the system, long-term presence of TNF-α would prove toxic to the tissue.   
Therefore, an engineered model of type II diabetes mellitus environment ex vivo is 
necessary to study ASC and adipose tissue behavior prior to utilization of such a model 
towards any anti-diabetic drug discovery study.  Additionally, a major limitation of 
studying adipocyte biology exists in the lack of long-term culture models for monitoring 
adipocyte behavior.  While adipocytes are able to cultured in two dimensions via ceiling 
culture, time points extending longer than 7-10 days are not possible due to 
dedifferentiation [130].  In order to address endocrine diseases such as type II diabetes, 
deeper assessment of adipocyte metabolism and functionality in vitro is necessary. 
1.4.3 Summary 
Adipose tissue, developed from the mesoderm, is vital as insulation and 
protection to mammalian organisms, but also as an endocrine organ [7, 19, 20].  As the 
presence of obesity ever increases in developed countries, a continuous learning and 
understanding of the relationship between adipose tissue, inflammation, and metabolic 
diseases remains critical.  The study of adipose-derived stem cells both in vitro and in 
vivo has provided a great deal of information to the behavior and potency of the stem 
cells, cell culture has been thoroughly established, and has provided several applications 
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in soft tissue reconstruction. Human ASCs in culture experience differences influenced 
by regional and anatomic locations, gender, and health; as a result, the murine 3T3-L1 
cell line is commonly utilized [52, 152, 153].  The most common pre-clinical model of 
engineering ASCs involves the mouse model in addition to GFP-labeling the cells as a 
method of characterization. 
Bioreactors pose influential and pivotal roles in tissue engineering and 
regenerative medicine, providing a longer, more accurate in vitro cell culture, shaping 
drug discovery and tissue explants.  Every bioreactor system is unique and several 
biomolecular and bioprocess parameters must be taken into consideration prior to each 
tissue engineering application.  
With diabetes mellitus on the rise in developed countries, countless studies are 
being conducted worldwide to address treatments and therapies to both types, I and II. 
Several pieces of work incorporating bioreactors into type I diabetes mellitus research 
include pancreatic cell line development and culture within a three-dimensional 
microgravity environment for long-term maintenance and assembly.  Conversely, 
bioreactor studies addressing type II diabetes mellitus appear to focus on lifestyle 
management and the side effect diseases associated with type II diabetes.  
While the use of bioreactors for pancreatic cell culture dates back to 1980 [154], 
the field has been validated, modified, and optimized over the past few decades; 
including kinetic modeling [155], mass transfer of insulin and glucose [156], oxygen 
consumption rate of islet culture [157], to list only a few.  Indeed, much room for 
advancement continues to exist in the field, fusing alterations on a classic biochemical 
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engineering tool and the fundamental yet constantly growing biomedical issue of diabetes 
mellitus.  
1.5 SPECIFIC AIMS AND HYPOTHESES 
In collaboration with the Bioreactor Laboratory in the McGowan Institute for 
Regenerative Medicine, our groups have developed an ex vivo three-dimensional, 
dynamic perfusion model to study adipose tissue function, resulting in the long-term 
culture (e.g. > 70 days) of metabolically active human adipose tissue derived from adult 
human patients [54].  Within the model, interwoven hollow fiber capillary bundles serve 
as physically active scaffolds for cell immobilization, where multi-compartment 
technology allows decentralized but high-performance mass exchange including integral 
oxygenation. 
The specific aims and hypotheses were designed to systematically examine adult 
human adipocyte function in an established, three-dimensional dynamic perfusion ex vivo 
bioreactor culture model as a potential tool for drug discovery.  
Specific Aim1: To analyze metabolic behavior and differentiation of ASCs derived from 
patients with type II diabetes mellitus within a hollow fiber-based, three-dimensional 
dynamic perfusion bioreactor.  The work performed towards Aim 1 is described in 
Chapter 2.  
Hypothesis: Adipose tissue culture and ASC differentiation is guided by environmental 
cues and, when exposed to similar culture environments, ASCs isolated from patients 
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with type II diabetes mellitus will behave similarly to ASCs isolated from patients 
without type II diabetes mellitus. 
Specific Aim 2: To establish a method to develop a physiologically relevant culture 
environment defined by a hindered insulin-dependent glucose uptake of cultured human 
adult adipose tissue within the bioreactor system.  The work performed towards Aim 2 is 
presented in Chapters 3. 
Hypotheses: ASCs can be differentiated and maintained as adipocytes at a physiological 
glucose concentration.  Stimulation by C2-Ceramide will inhibit insulin-stimulated 
glucose uptake of the adipocytes within the bioreactor system. 
Specific Aim 3: To further enhance the adipose tissue ex vivo by optimizing homogeneity 
within the bioreactor culture. The work performed towards Aim 3 is reported within 
Chapter 4. 
Hypothesis: Inclusion of a decellularized, adipose tissue extracellular matrix (ECM) 
hydrogel within the ex vivo bioreactor culture system will enhance ASC differentiation to 
the adipocyte lineage and improve adipose tissue homogeneity within the bioreactor.  
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2.0 METABOLIC BEHAVIOR AND DIFFERENTIATION OF ADIPOSE-
DERIVED STEM CELLS FROM PATIENTS WITH TYPE II DIABETES 
MELLITUS WITHIN A HOLLOW FIBER-BASED, THREE-
DIMENSIONAL, DYNAMIC PERFUSION BIOREACTOR. 
2.1 INTRODUCTION 
2.1.1  Type II Diabetes Mellitus 
Type II diabetes and obesity have recently become epidemics in developed 
countries.  According to the Centers for Disease Control and Prevention, diabetes affects 
25.8 million people in the United States, or 8.3% of the country’s population, and 35.7% 
of American adults are considered to be obese [158, 159].   As the nation’s obesity rate 
continues to escalate, further understanding on the role of adipose tissue in disease states 
becomes more significant. 
Both types I and II diabetes mellitus are characterized by the lack of insulin-
stimulated glucose transport from blood to tissue, a consequence of β-cell failure in the 
pancreas [105].  Simply, type I diabetes mellitus is a result of β-cell apoptosis activated 
by cytokines produced by invading immune cells. Type II diabetic patients experience β-
cell dysfunction resulting from elevated levels of glucose and free-fatty acids (FFAs), 
consequences of increased adipocyte size and body mass [20].  Healthy levels of insulin 
cannot adequately transport the elevated amount of glucose into muscle, fat, and liver to 
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be broken down into energy.  In response, β-cells of the pancreas become exhausted 
producing more insulin, eventually leading to β-cell apoptosis in addition to the high 
glucose and insulin levels in the bloodstream [160].  Insulin resistance is a defining 
characteristic of the pre-diabetic state and typically precedes type II diabetes 
development unless a drastic lifestyle change is enforced involving extreme weight less 
and physical activity. 
2.1.2  Bioreactor Design 
The multi-compartment bioreactor system utilized in the presented thesis involves 
two interwoven networks of porous hollow-fiber membrane polysulfone bundles intended 
for medium perfusion and a third interwoven network of oxygenation hollow fibers on 
which the cells are seeded and cultured, providing a decentralized oxygenation and 
uniform nutrient and gas exchange with physiological gradients to the tissue (Fig. 8) [54]. 
  The extracapillary space forms a compartment in which cells are inoculated; the 
total cell compartment inside the three-dimensional hollow fiber-based bioreactor volume 
is 8 mL. Run via external perfusion systems and pumps, the continuous media perfusion 
and gas flow through the system can be tailored and have been optimized, based on 
several previous reports on such bioreactors used for hepatocyte progenitors and 
embryonic stem cell cultures [161-165].  The bicarbonate buffer system and carbon 
dioxide gas exchange regulate pH of the entire cell compartment volume with negligible 
shear stress, creating a permitting environment for sustained, long-term cultures of tens of 
millions of cells without mechanical stimuli [54].  Previous work further explaining the 
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development of such bioreactor system as applied to adipocyte culture is featured in 
Gerlach, et al [54]. 
2.1.3 Chapter Aims 
The work described in this chapter aims to develop a reproducible, ex vivo process 
to study the metabolic activity and adipogenesis of human ASCs within a hollow fiber-
based bioreactor for three-dimensional perfusion to function as a potential model for drug 
discovery, specifically type II diabetes mellitus.  The studies in Chapter 2 hypothesize 
that adipose tissue culture and ASC differentiation is guided by environmental cues and, 
when exposed to similar culture environments, ASCs isolated from patients with type II 
diabetes mellitus will behave similarly to ASCs isolated from patients without type II 
Figure 8. Hollow fiber-based bioreactor setup.  A) Photograph of an 8 mL-volume hollow 
fiber-based bioreactor used; B) Bioreactors incorporated onto the perfusion system and pumps as 
utilized in the presented work; C) Schematic of nutrient/gas flow in and out of the bioreactor cell 
compartments through the porous, hollow fiber membranes [54].  
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diabetes mellitus.  Presented work includes the analysis and comparison of metabolic 
behavior and functionality of human ASCs isolated from adult patients with type II 
diabetes and non-diabetic patients.  Such ASCs cultured and differentiated into 
adipocytes within a three-dimensional, hollow fiber-based bioreactor is presented.   
2.2 MATERIALS AND METHODS 
2.2.1 ASC Isolation
Adipose tissue was harvested from the abdominal depots of type II diabetic 
female patients (39 and 62 years old, body mass index (BMI) of 27.4 and 32.0, 
respectively) and from female patients without diabetes (55 and 25 years old, BMIs of 
25.5 and 28.6, respectively), all undergoing elective plastic surgery at the University of 
Pittsburgh Medical Center in Pittsburgh, PA, USA.  Tissue was collected under a human 
studies exempt protocol approved by the University of Pittsburgh Institutional Review 
Board (IRB).  The University of Pittsburgh waived the need for written informed consent 
from the participants under an exempt review and approval process. Samples were not 
pooled between diabetic and non-diabetic patients rather; cells from two separate diabetic 
samples were combined in one instance to provide sufficient number of cells required for 
optimal inoculation and cell-to-cell communication within the bioreactor (Table 4, 
Bioreactor #4).  Non-diabetic patients were not pre-diabetic and did not have insulin 
resistance at time of adipose tissue harvesting.   
Abdominal adipose tissue was placed in 50 mL centrifuge tubes at 10 g per tube 
and soaked in 1 mg·mL
-1
 of freshly prepared collagenase (Type II collagenase,
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Worthington Biochemical Product Catalog; Lakewood, NJ, USA).  The tissue was finely 
minced, vortexed, and shaken at 37 °C for 35 minutes until a fatty supernatant layer 
became apparent.  Tubes were again vortexed and filtered through double-layered gauze 
(J&J Steri-Pad Gauze Pads; New Brunswick, NJ, USA) into sterile 50 mL centrifuge 
tubes.  Digested specimens were then centrifuged at 1000 rpm (6449 x g), 4 °C for 10 
minutes, fatty layers aspirated, and resulting pellets suspended in erythrocyte lysing 
buffer.  The solution was once again centrifuged at 1000 rpm (6449 x g), 4 °C for 10 
minutes and the pellet, containing the stromal vascular fraction, was resuspended in 
Dulbecco’s Modified Eagle’s Medium (DMEM/F12) with 10% v/v fetal bovine serum 
and 1% v/v penicillin/streptomycin, plated, and stored at 37 °C at 5% CO2.  Cells were 
expanded in two dimensions using growth medium with low serum (Promocell 
Preadipocyte Growth Medium, Heidelberg, Germany), passaged at confluency, and 
characterized as previously described by our laboratory [56].  
2.2.2 Bioreactor Inoculation 
The bioreactors are prototyped by Stem Cell Systems (Berlin, Germany) and 
contain three independent hollow fiber membrane systems, interwoven into repetitive 
subunits, forming a cell compartment that houses 8.0 × 10
7
 cells with a volume of 8 mL
(Fig. 7).  The capillary network serves three functions: cell oxygenation/carbon dioxide 
removal, medium inflow, and medium outflow via countercurrent flow operation of two 
independent membrane systems.  As a result of interweaving and high performance mass 
exchange via counter-current medium flow operation, decentralized gas supply and 
medium exchange with low gradients is provided to the cultures.  The medium fiber 
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membrane systems are made of polyethersulfone capillary systems (Membrana, 
Wuppertal, Germany) with a molecular weight cutoff of 400,000 g·mol
-1
 and gas is
supplied by hydrophobic multi-laminate hollow fiber membrane systems (MHF; 
Mitsubishi, Tokyo, Japan).  
A total of six bioreactor experiments were performed: three bioreactors cultured 
with ASCs from females diagnosed with type II diabetes mellitus at time of surgery, and 
three bioreactors cultured with ASCs from healthy, non-obese, females without type II 
diabetes.  Bioreactor sterilization was performed with ethylene oxide gas and degassed 
with air.  Before cells were introduced into the system, a continuous phosphate buffered 
solution flush was run within the bioreactor for 72 hours, followed by priming with 
DMEM/F12 media flush for 24 hours prior to inoculation.  Cell suspensions of 8.0 × 10
7
total cells per bioreactor were inoculated and cultured throughout a time period of six 
weeks.  The cell compartments were continuously perfused with culture media through 
the polyethersulfone hollow fiber bundles at a feed rate of 4 mL·hr
-1 
in combination with
a recirculation loop at a rate of 20 mL·min
-1
.  Waste medium was removed from the
circuit at 4 mL·hr
-1
.  The flows of compressed air and carbon dioxide in the gas
compartment were maintained at 20 mL·min
-1
.  Partial pressures of oxygen, carbon
dioxide, and acid/base status within the bioreactor were measured daily and the carbon 
dioxide content was adjusted throughout culture time to maintain the medium pH within 
the range of 7.35-7.45. 
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Table 4. Patient age, gender and BMI relative to diabetic state at time of ASC 
isolation used for bioreactors in Specific Aim 1.  
2.2.3 Cell Culture 
Cells were inoculated into the bioreactor cell compartments via a suspension of 
8.0 x 10
7 
cells per mL of medium.  Cell passages at time of inoculation for each
experiment were either passage 3 or 5 and are described in Table 4.  Upon completion of 
a twenty-one day expansion period of the ASCs within the bioreactor cell compartment 
by perfusion of ASC plating media (DMEM/F12 as described above), to initiate three-
dimensional adipogenic differentiation, the feed media was changed for the following 
fourteen days to adipogenic media containing DMEM/F12, HEPES, biotin, pantothenate, 
human insulin, dexamethasone, 3-isobutyl-1-methylxanthine (IBMX), PPAR-γ agonist, 
and antibiotics (ZenBio, Research Triangle Park, NC, USA).  Adipocytes were 
maintained for seven days with feed media containing DMEM/F12, HEPES, fetal bovine 
serum, biotin, pantothenate, human insulin, dexamethasone, and antibiotics (ZenBio).  
Cells were not further passaged within the bioreactor; rather, cell fate was influenced by 
changes in culture medium. 
Bioreactor # Patient Age Gender BMI Diabetic? Patient # 
Cell 
Passage # 
1 35 Female 28.6 No 1 3 
2 55 Female 25.5 No 2 3 
3 55 Female 25.5 No 2 3 
4 62 Female 32.0 Yes 3 5 
4 39 Female 27.4 Yes 4 5 
5 39 Female 27.4 Yes 4 5 
6 39 Female 27.4 Yes 4 5 
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In parallel, ASCs in a two-dimensional control group were cultured in 175 cm
2
tissue culture flasks with ASC plating medium containing 10% v/v fetal bovine serum 
and 1% v/v penicillin/streptomycin, plated, and stored at 37 °C at 5% CO2.  2D control 
ASCs were cultured for three weeks, with static media changes every other day and 
passaged at 80% confluency.  2D controls were stored for gene and protein assessment. 
2.2.4 Metabolic Activity Analysis 
Glucose production and consumption of the cells throughout culture within the 
bioreactors was assessed under a dynamic open-circuit system.  A sampling volume of 2 
mL was taken daily via a luer-lock sample port; glucose and lactate dehydrogenase levels 
measured (YSI 2300 STATE Plus Glucose & Lactate Analyzer; YSI Life Sciences, 
Yellow Springs, OH, USA; Quantichrom Lactate Dehydrogenase Kit; BioAssay Systems, 
Hayward, CA, USA).  
Glucose production/consumption rates of the cells were determined by a 
previously established protocol considering various parameters including measured 
glucose concentration within the recirculation sample, total system volume, baseline 
medium concentrations, flow rate of nutrients through the system, and time points of 
measurements [161-165, Eqns 2 and 3].  
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2.2.5 Tumor-Necrosis Factor-α Functional Testing 
After seven days of maintenance, adipocytes within all six bioreactor cultures 
underwent exposure to 10 ng·mL
-1
 direct injection of tumor necrosis factor (TNF)-α
(Roche Applied Sciences, San Francisco, CA, USA) intended to inhibit glucose uptake 
by the adipocytes.  TNF- α exposure lasted for 24 hours and glucose production was 
measured every 30 minutes.  Feed inlet and waste outlet flow rates were set to 10 mL·hr
-1
to ensure that the entire circuit volume was replaced every hour.  Throughout TNF-α 
exposure, media containing 10 ng·mL
-1
 dosage of TNF-α and no insulin was delivered to
the tissue with intention of hindering glucose consumption of the adipocytes.  
Once glucose consumption/production had stabilized after 24 hours of TNF-α 
delivery, all six bioreactors were stimulated with human insulin as a “recovery” (Sigma-
Aldrich, St. Louis, MO, USA) by a 5 μM direct injection in addition to delivering feed 




After the 8-hour stimulation period, feed medium was returned to non-insulin containing 
medium and glucose consumption measurements were continued for another 20 hours to 
confirm adipocyte metabolism had returned to baseline before bioreactor disassembly. 
2.2.6 Immunohistochemistry and Histology 
Upon termination of each bioreactor culture, tissue/fiber samples were extracted 
from the bioreactors and placed in 10% w/v buffered formalin (Thermo Scientific) and 
stored at 4 °C in the formalin for fixed histology samples.  Samples were stained with 
AdipoRed Assay Reagent to analyze lipid inclusion (Lonza, Walkersville, MD, USA).  
Samples were protected from light and incubated at room temperature with AdipoRed 
staining dilutions according to Lonza protocol for 40 minutes, then exposed to DAPI (0.6 
μg/mL, Invitrogen) and AlexaFluor 488 Phalloidin (6.6 μM, Invitrogen) to stain for 
nuclei and F-actin, respectively, for 10 minutes at room temperature.  
Immunofluorescence was captured from an Olympus Fluoview 1000 Upright Confocal 
Microscope (Olympus America, Melville, NY, USA).  
Additionally, samples were paraffin embedded, stained with hematoxylin & eosin 
and Masson’s Trichrome, and imaged under bright field microscopy of an Olympus 
Provis Light Microscope (Olympus America) for architectural assessment and to 
determine matrix formation.  
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2.2.7 Scanning Electron Microscopy 
Bioreactor explants stored at 4 °C in formalin were air dried and placed onto 
metal stubs covered in double-sided copper tape.  The fibers were then gold-sputtered to 
a density of 3.5 mm from Cressington 108 auto sputter-coater (Cressington, Watford, 
UK) and imaged with a JEM-6330f Scanning Electron Microscope (Jeol, Peabody, MA, 
USA).  Scope was operated at 5kV acceleration.  
2.2.8 Gene Expression 
Tissue samples from all six bioreactor cultures were stored in RNAlater 
Stabilization Reagent (Qiagen, Valencia, CA, USA) at 4 °C for qPCR.  mRNA was 
collected using Qiagen RNeasy mini Kit and reverse-transcribed into cDNA using First 
Strand Transcription Kit (Invitrogen, Carlsbad, CA, USA), both according to the 
manufacturer’s protocol.  PCR primers were designed using Invitrogen’s Vector NTI and 
synthesized by Invitrogen.  
qPCR was performed in triplicate in 96-well optical plates and the primer 
sequences are as follows: peroxisome proliferator-activated receptor (PPAR)-γ forward: 
5′-CGAGAAGGAGAAGCTGT TGG-3′; PPAR-γ reverse: 5′-
TCAGCGGGAAGGACTTTATGTATG-3′; fatty acid binding protein (FABP)4 forward: 
5′-AGCACCATAACCTTAGATGGGG-3′; FABP4 reverse: 5′-
CGTGGAAGTGACGCCTTTCA-3′; glyceraldehyde 3-phosphate dehydrogenase 
(GAPHD) forward: 5’ACAGTCAGCCGCATCTTCT-3’; GAPDH reverse: 5’-
ACGACCAAATCCGTTCACT-3’; where GAPDH was applied as a housekeeping gene.   
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2.2.9 Protein Expression 
Cells were scraped from bioreactor fibers stored in RNAlater at 4 °C using Cell 
Scrapers from BD Falcon (Franklin Lakes, NJ, USA), centrifuged for 10 minutes at 2,000 
rpm (12989 x g), resuspended in sample buffer (NuPAGE LDS Sample Buffer, 
Invitrogen), and boiled for 5 minutes in water.  10% w/v SDS-based gels were made and 
loaded with protein marker, 5 μg of positive and negative controls (whole fat sample and 
two-dimensional ASCs, respectively), and equal samples amounts of cells from diabetic 
and non-diabetic bioreactors.  Gels were run, electrophoretically transferred to 
membranes (Immobilon Transfer Membranes, Sandwiches, and Blotting Filter Paper; 
Millipore, Billerica, MA, USA), and blocked with 5% w/v milk (Skim Milk Powder; 
EMD Chemicals Inc., Darmstadt, Germany) for one hour.  Membranes were stored 
overnight at 4 °C in rabbit polyclonal anti-PPAR-γ (Abcam, Cambridge, MA, USA) at 
1:1000 dilution, or mouse polyclonal anti-GAPDH (Abcam) at 1:1000 dilution.  After 
overnight primary antibody incubation, membranes were washed three times with buffer 
solution (Bio-Rad, Hercules, CA, USA) containing Tween-20 followed by soaking in 
rabbit or mouse polyclonal secondary antibodies (Jackson Immuno Research, West 
Grove, PA USA) at 1:50,000 dilution for 60 minutes at room temperature.  Membranes 
were then washed three times with buffer solution containing Tween-20 (Acros Organics, 
Geel, Belgium) and detected using SuperSignal detection agent (SuperSignal West Femto 
Maximum Sensitivity Substrate; Thermo Scientific, Pittsburgh, PA, USA).  Membranes 
were taken into a dark room where they were developed onto x-ray film (Blue X-Ray 
Film; Phenix Research Products, Candler, NC, USA) with a phosphor screen (Storage 
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Phosphor Screen; Kodak, Rochester, NY, USA) and processed (X-OMAT 2000 
Processor; Kodak). 
2.2.10 Statistical Methods 
Results are presented as mean ± standard deviation.  Unpaired, two-tailed t-tests 
were performed to assess differences in metabolic activity between treatment groups. 
One-way ANOVA followed by Games-Howell post hoc testing was used to determine 
differences in gene expression between groups.  All data were found to be normally 
distributed and variances were homogenous.  Statistical significance is determined at p-
values less than 0.05. 
2.3 RESULTS AND DISCUSSION 
2.3.1 Metabolic Activity 
Figure 9 represents average glucose production within the bioreactors of the cells 
and tissue using aforementioned protocol during ASC expansion (days 0-21), ASC 
differentiation into adipocytes (days 22-36), and adipocyte maintenance (days 37-45) 
within all six bioreactors, where solid squares signify glucose production/consumption of 
cells from diabetic patients and empty squares denote cells from non-diabetic patients.  
Lactate dehydrogenase (LDH) was measured daily to monitor damage to plasma 
membranes.  No increase in LDH concentration within the recirculation media was 
observed throughout bioreactor culture nor was there any significant difference in LDH 
concentration between diabetic and non-diabetic ASCs. 
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Over the entire 45-day culture, glucose production of ASCs from diabetic patients 
is no different – with the exception of one time point, which had a p-value of 0.0498 – 
within the bioreactor from glucose production of ASCs from non-diabetic patients, up to 
a confidence interval of 95% with N-value of 3.  Throughout bioreactor culture, average 
glucose production/consumption of tissue from diabetic samples appeared to remain 
steady; whereas, tissue from non-diabetic samples exhibited sharply decreased glucose 
consumption upon differentiation.  Such change in glucose uptake could be due to the 
cells preparing for differentiation, saturation and storing of glucose for lipid accumulation 
[164-168].   
Figure 9. Metabolic activity. Glucose production/consumption trends of three bioreactors seeded 
with ASCs from non-diabetic patients (empty squares) and three bioreactors seeded with ASCs from 
type II diabetic patients (filled squares) over 45 days of culture.  Days 0-21 represent a time period in 
which ASCs were allowed to expand within the bioreactor; throughout days 22-36 ASCs were 
influenced to differentiate into adipocytes by a medium change; adipocytes were maintained from 
days 37-45.  Glucose consumption is predominantly not significantly different (* p = 0.0498, N=3) 
within tissue derived from diabetic patients as to tissue derived from patients without diabetes. 
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2.3.2 TNF-α Functional Testing 
Figure 10 depicts the average glucose production of all six bioreactors (three each 
from diabetic and non-diabetic groups) before, during, and after insulin stimulation of the 
three-dimensional adipose tissue.  Results indicate no significant difference between 
glucose consumption/production of adipocytes generated from diabetic ASCs and those 
from non-diabetic ASCs within the hollow fiber-based bioreactor (p> 0.05, N=3) before 
and after insulin stimulation.  During insulin stimulation, bioreactors containing samples 
from diabetic patients experienced less glucose consumption than those from non-
diabetic patients in three of the sixteen time points measured, with a N-value of 3 and p-
values of 0.010, 0.043, and 0.023.  
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2.3.3 Immunohistochemistry 
Imaging results of the tissue generated within the bioreactors are shown in Figures 
8-10.  Macroscopic tissue formation was observed in and around the hollow fiber
membranes upon bioreactor disassembly [Figures 11 and 12].  Regarding both groups of 
adipose tissue – that differentiated from ASCs obtained from diabetic patients and that 
Figure 10. Adipocyte functionality. All six bioreactors were stimulated with TNF-α for twenty-
four hours, glucose consumption was measured and noted to be hindered.  After reaching a steady 
glucose consumption rate, insulin was introduced to the system and the functional adipocytes 
were able to recover from the TNF-α dosage as glucose consumption increased.  Tissue from 
diabetic patients (filled squares) functions with mostly no significant difference (* p < 0.05, N=3) 
to tissue from patients without diabetes (empty squares) when stimulated with TNF-a and insulin. 
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from non-diabetic patients – histological analyses revealed closely associated adipocytes 
throughout all bioreactors and confocal fluorescent imaging identified AdipoRed lipid 
formation after 45 days of culture within the dynamic perfusion systems, while DAPI and 
AlexaFluor 488 Phalloidin highlight nuclei and F-actin, respectively 
2.3.4 Histology 
Imaging results of the tissue generated within the bioreactors are shown in Figures 
11 and 12.  Macroscopic tissue formation was observed in and around the hollow fiber 
membranes upon bioreactor disassembly [Figures 11 and 12].  Regarding both groups of 
adipose tissue – that differentiated from ASCs obtained from diabetic patients and that 
from non-diabetic patients – histological analyses revealed closely associated adipocytes 
throughout all bioreactors.  
Figure 11. Immunohistochemistry. End-point (45 days) AdipoRed/DAPI/Phalloidin 
immunohistochemistry from bioreactors containing adipose tissue generated from patients 
without (A) or with (B) type II diabetes mellitus at 20X, scale bar = 100 μm. Red = 
AdipoRed, blue = DAPI, green = AlexaFluor 488 Phalloidin.  
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2.3.5 SEM 
SEM images of the samples removed from all bioreactors reveal cell growth on 
and among the hollow fibers [Fig. 13].  White arrows on Figure 10 indicate adipocytes.  
. 
Figure 12. Histology. End-point (45 days) histology from bioreactors containing adipose 
tissue generated from patients without (A, B) or with (C, D) type II diabetes mellitus; where 
A and C are H&E, and B and D are Masson’s Trichrome, all images captured at 40X 
magnification, scale bar = 100 μm. 
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2.3.5 Gene and Protein Expression 
Results obtained from qPCR confirm FABP4 and PPAR-γ gene expression of the 
adipose tissue generated within all six of the bioreactors, with no significant difference in 
FABP4 gene expression between adipose differentiated from diabetic and non-diabetic 
ASCs as determined by one-way ANOVA (F(4,10) p> 0.05) [Fig. 14].  A Games-Howell 
post-hoc test confirmed that FABP4 gene expression in whole fat was statistically 
significantly higher than FABP4 gene expression in ASCs (p< 0.05) and was not 
statistically different from FABP4 gene expression in samples extracted from both 
diabetic and non-diabetic bioreactor cultures p> 0.05, N=3) [Fig. 14]. PPAR-γ gene 
expression was found to be statistically significantly higher in whole fat compared to 
both 2D ASCs controls and samples extracted from the diabetic bioreactor culture (p < 
Figure 13. Scanning Electron Micrographs. Scanning Electron Microscopy (SEM) images of 
adipocytes on fibers extracted from bioreactors after 45 days of culture inoculated with ASCs 
from (A-D) patients without type II diabetes mellitus and (E-H) patients with type II diabetes 
mellitus. Adipose tissue is indicated by white arrows at 45X and 100X. 
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0.05, N=3), whereas, PPAR-γ gene expression was not significantly different in samples 
extracted from the non-diabetic bioreactor culture (p > 0.05, N=3) [Figure 14]. 
PPAR-γ and GAPDH protein expression was exhibited by adipose tissue from 
bioreactors with diabetic and non-diabetic ASCs as well as whole fat samples [Fig. 15]. 
While housekeeping protein, GAPDH, confirmed presence of protein in all samples, 
including two-dimensional ASCs, two-dimensional ASCs did not express PPAR-γ 
protein, reaffirming the maturity of adipose tissue cultured within the three-dimensional, 
hollow fiber-based, dynamic perfusion bioreactors.   
Figure 14. Gene Expression. A) Fatty Acid Binding Protein-4 (FABP4, solid white bars) and B) 
Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ, dotted white bars) gene expression is 
significantly higher (p< 0.05*,) in native whole adipose tissue than in ASCs grown in 2D culture. 
PPAR-γ gene expression was higher in native whole adipose tissue compared to both 2D ASCs 
controls and samples extracted from the diabetic bioreactor culture (p < 0.05, N=3), whereas, 
PPAR-γ gene expression was not significantly different in samples extracted from the non-
diabetic bioreactor culture (p > 0.05, N=3) . 
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2.4 CONCLUSIONS 
Human adipose-derived stem cells derived from adults with type II diabetes 
mellitus were cultured within hollow fiber-based membrane, three-dimensional, dynamic 
perfusion bioreactors for 45 days and metabolic behavior was assessed along with gene 
and protein expression.  Glucose consumption following TNF-α exposure increased 
during insulin influence, confirming functionality of the generated adipocytes.  Masson’s 
Trichrome, H&E, AdipoRed images in addition to FABP4 and PPAR-γ gene expression 
and PPAR-γ protein expression of the functional adipocytes show no major difference 
between adipose tissue generated in three dimensions when isolated from patients with or 
without type II diabetes mellitus, raising the question of whether the ASCs retain a 
diseased state when cultured in vitro; and how environment affects functionality of 
human adipose cells in three-dimensional culture.  Following massive weight loss, 
change in diet and exercise, patients with type II diabetes mellitus experience regression 
of the insulin-stimulated uptake and lowered blood glucose levels [169].  As type II 
Figure 15. Protein Expression. Images obtained from Western Blots measuring protein 
expression of PPAR- γ or GAPDH of ASCs cultured in two dimensional tissue culture flasks as a 
negative control, whole fat sample as a positive control, adipose tissue cultured within the 
bioreactors over 45 days from diabetic patients, and adipose tissue cultures within the bioreactors 
from non-diabetic patients. 
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diabetes mellitus is clinically reversible, this data supports the hypothesis that human-
derived ASCs experience plasticity in culture, dependent on environment. The presented 
work provides a first step to advance better understanding of adipose tissue as a whole-
body endocrine organ and it’s key role in metabolic diseases.   
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3.0 ADIPOCYTE DIFFERENTIATION CULTURE MEDIA 
OPTIMIZATION OF PHYSIOLOGICALLY RELEVANT GLUCOSE 
CONCENTRATIONS AND DEVELOPMENT OF A TYPE II 
DIABETIC ENVIRONMENT IN VITRO AND EX VIVO 
CHARACTERIZED BY HINDERED INSULIN-STIMULATED 
GLUCOSE UPTAKE 
3.1 INTRODUCTION 
3.1.1 Insulin-Stimulated Glucose Consumption by Adipose Tissue 
Adipocytes store lipid in the form of triglycerides, which are presented to the 
adipocyte in the form of a glycerol molecule and three fatty acid chains.  Outlined in 
Figure 16, once the free fatty acids (FFAs) are transported into the adipocyte, 
triglycerides are reformed and stored inside the lipid droplet.  Hormone sensitive lipase 
and lipoprotein lipase regulate triglyceride entry, storage, and release in the adipocytes.  
Additionally featured in Figure 16 is the action of insulin within the adipocyte.  Once 
insulin is accepted by its receptors and brought into the cell, glucose transporter (GLUT) 
4 is able to translocate about the membrane and glucose is taken by the adipocyte.  An 
abundance of insulin and glucose in the blood stream – a result of the metabolic 
syndrome and characteristic of type II diabetes – inhibits and exhausts the insulin 
receptors and, ultimately, the action of GLUT4. 
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 When adipocytes increase in size and a person gains weight, several molecular 
and cellular changes occur and ultimately influence whole-body metabolism [170-179].  
Horowitz et al., identified higher free fatty acid and glycerol levels in obese women 
compared to lean women, suggesting a promotion of insulin resistance – the primary 
cause of type II diabetes [28, 180].  In addition to FFA, with a strong presence in those 
with obesity, various other proinflammatory factors are secreted by adipose tissue, 
including IFNγ, TNF-α, MCP-1, IL-6, IL-1β, and several immune cells [Fig. 16]. 
Figure 16. Select molecular mechanisms of an adipocyte.  Model of an adipocyte and select 
molecular mechanisms of the synthesis and degradation of triacylglyercols by adipose 
tissue in addition to insulin receptor and GLUT4 mechanisms. 
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Discussed in Chapter 2, ASCs retain no memory of diabetic function when placed 
in a different culture environment.  Because microenvironment is highly influential ex 
vivo, in order to study type II diabetes mellitus, an engineered culture model is necessary.   
Summers et al., [122, 180] found that C2-ceramide, (a short analog of ceramide, a 
sphingolipid-fatty acid component of sphingomyelin within the cell membrane lipid 
bilayer), inhibited glucose transport and GLUT4 translocation in 3T3-L1 adipocytes (a 
cell line commonly utilized in studying adipose tissue) in two dimensional in vitro cell 
culture.  
3.1.2 ASC and Adipocyte Culture Medium Compositions 
A widely accepted and used ASC expansion medium consists of a DMEM and 
DMEM/F12media combination, with 10% fetal bovine serum, some form of antibiotic 
(typically penicillin/streptomyocin), and typically a miniscule amount of dexamethasone, 
which prevents any differentiation into another mesenchymal lineage, such as osteoblasts.  
The glucose concentration of ASC expansion medium is typically around 400 mg/dL, but 
may vary between batches.  Adipocyte differentiation medium produced by ZenBio (item 
# DM-2) consists of DMEM and Ham’s F-12 1:1 v/v combination, with fetal bovine 
serum, biotin, pantothenate, human insulin, dexamethasone, isobutylmethylzanthine, 
PPARγ agonist, penicillin, streptomycin, and amphotericin B. ZenBio adipocyte 
maintenance medium (item # AM-1) consists of DMEM and Ham’s F-12 1:1/v/ 
combination, with fetal bovine serum, biotin, pantothenate, human insulin, 
dexamethasone, penicillin, streptomycin, and amphotericin B.  Untouched, the glucose 
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concentrations of both differentiation and maintenance medium are around 300 mg/dL.  
Table 4 further compares notable relevant glucose concentrations.  
Because the manufactured ZenBio differentiation and maintenance medium 
contain glucose levels almost 3 times higher than the normal fasting blood glucose level 
of an adult human (300 mg/dL in culture medium, compared to 110 mg/dL), a more 
thorough investigation is necessary to determine if the similarity between metabolic 
activity of the adipocytes generated from diabetic versus non-diabetic ASCs observed in 
Chapter 2 is a result of the stem cells not retaining the diseased state, or a consequence of 
the relatively elevated glucose levels in the culture medium. 
3.1.3 Chapter Aims 
The work presented in this chapter aims to first establish an in vitro method to 
develop a physiologically relevant culture environment defined by a hindered insulin-
dependent glucose uptake of differentiated ASCs in two dimensions.  The findings 
uncovered from this chapter are to be eventually applied towards the cultured human 
adipose tissue within the hollow fiber-based, three dimensional dynamic perfusion 
bioreactor system, which is further detailed later in Chapter 3.  It is hypothesized that 
ASCs can be differentiated and maintained as adipocytes at a physiological glucose 
concentration.  Stimulation by C2-Ceramide and free fatty acids will inhibit insulin-
stimulated glucose uptake of the differentiated ASCs in vitro in two dimensions. 
The study described in this chapter aims to apply the results investigated in 
Chapter 3 to first establish a method to develop a physiologically relevant culture 
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environment defined by a hindered insulin-dependent glucose uptake of cultured human 
adult adipose tissue within the hollow fiber-based, three dimensional, dynamic perfusion 
bioreactor system.  It is hypothesized that ASCs can be differentiated and maintained as 
adipocytes at a physiological glucose concentration within the bioreactor system and that 
stimulation by C2-Ceramide will inhibit insulin-stimulated glucose uptake of the cultured 
adipocytes. 
3.2 MATERIALS AND METHODS 
3.2.1 Human ASC Isolation  
Adipose tissue was harvested from the abdominal depots of non-diabetic female 
patients (66 and 61 years old, body mass index (BMI) of 38.4 and 30.7, respectively) 
undergoing elective plastic surgery at the University of Pittsburgh Medical Center in 
Pittsburgh, PA, USA.  Tissue was collected under a human studies exempt protocol 
approved by the University of Pittsburgh Institutional Review Board (IRB).  The 
University of Pittsburgh waived the need for written informed consent from the 
participants under an exempt review and approval process. Samples were pooled to 
provide sufficient number of cells required for optimal seeding.  Donors were not pre-
diabetic and did not have insulin resistance at time of adipose tissue harvesting.   
Abdominal adipose tissue was placed in 50 mL centrifuge tubes at 10 g per tube 
and soaked in 1 mg·mL
-1
 of freshly prepared collagenase (Type II collagenase,
Worthington Biochemical Product Catalog; Lakewood, NJ, USA).  The tissue was finely 
minced, vortexed, and shaken at 37 °C for 35 minutes until a fatty supernatant layer 
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became apparent.  Tubes were again vortexed and filtered through double-layered gauze 
(J&J Steri-Pad Gauze Pads; New Brunswick, NJ, USA) into sterile 50 mL centrifuge 
tubes.  Digested specimens were then centrifuged at 1000 rpm (6449 x g), 4 °C for 10 
minutes, fatty layers aspirated, and resulting pellets suspended in erythrocyte lysing 
buffer.  The solution was once again centrifuged at 1000 rpm (6449 x g), 4 °C for 10 
minutes and the pellet, containing the stromal vascular fraction, was resuspended in 
Dulbecco’s Modified Eagle’s Medium (DMEM/F12) with 10% v/v fetal bovine serum 
and 1% v/v penicillin/streptomycin, plated, and stored at 37 °C at 5% CO2.  Cells were 
expanded in two dimensions using growth medium with low serum (Promocell 
Preadipocyte Growth Medium, Heidelberg, Germany), passaged at confluency, and 
characterized as previously described by our laboratory [56].  
3.2.2 In Vitro Cell Culture 
ASCs were plated onto 96-well plates at 10,000 cells per well, then differentiated 
for a period of seven days using the ZenBio differentiation media as a positive control, 
various dilutions of our laboratory’s in-house differentiation medium stepwise from 100, 
50, 35, 30, 25, 20% and a negative control of ASC expansion media.  Cultures were then 
maintained using ZenBio maintenance medium for another seven days.  In-house 
differentiation media was diluted with no-glucose DMEM, according to Table 5. 
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Table 5. Relevant Glucose Concentrations. 
Medium Glucose Level (mg/dL) 
100% ZenBio differentiation 352 
100% ASC expansion 416 
100% In-house differentiation 454 
50% Diluted in-house diff 258 
35% Diluted in-house diff 164 
30% Diluted in-house diff 139 
25% Diluted in-house diff 118 
20% Diluted in-house diff 96.3 
Type II diabetic patient, fasting 
physiological 
> 140
Healthy adult, fasting physiological 70-130
In a separate study to test hindered ASC glucose consumption and to determine an 
optimal dosage of C2-ceramide as well as appropriate FFA concentrations to be delivered 
to the tissue within the bioreactor was examined by manipulating human adult ASCs in 
96-well plates.  Media containing FFA was freshly prepared using a stock solution of
FFA (“Ex-cyte”) as manufactured by Millipore.  ASCs were isolated following the same 
protocol described above (Chapter 3.2.1.) plated onto 96-well plates at 10,000 cells per 
well, differentiated for a period of seven days using the optimized, diluted differentiation 
media at either 35 or 20%, then maintained for seven days in the well plates using the 
same ZenBio maintenance media.  During the seven-day maintenance period, adipocytes 
in the 96-well plates were exposed to various concentrations of C2-ceramide and FFAs as 
follows: 150 μM C2-ceramide + FFA, 100μM C2-ceramide + FFA, 25 μM C2-ceramide 
+ FFA, 150 μM C2-ceramide, 100 uM C2-ceramide, 25 μM C2-ceramide, FFA only,
maintenance medium only at 35% diluted differentiation, maintenance medium only at 
20% diluted differentiation, ASC expansion medium only. 
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3.2.3 In Vitro Metabolic Activity Analysis 
Glucose consumption and lactate production was analyzed by removing 100 μL of 
medium supernatent from each well daily and measured with YSI Glucose & Lactate 
Analyzer.   
3.2.4 Adipogenesis and Nuclei Characterization & Quantification  
Upon in vitro experiment completion, 96-well plates were fixed by 4% 
paraformaldehyde for 30 minutes.  Samples were stained with AdipoRed Assay Reagent 
to analyze lipid inclusion (Lonza, Walkersville, MD, USA).  Samples were protected 
from light and incubated at room temperature with AdipoRed staining dilutions according 
to Lonza protocol for 40 minutes, then exposed to DAPI (0.6 μg/mL, Invitrogen).  Plates 
were read and fluorescence quantified on a Tecan Infinite 200 PROplatereader 
(Mannedorf, Switzerland), then imaged on an Olympus Provis fluorescence microscope 
(Olympus America) to gauge lipid inclusion and nuclei assessment.  The dilution to yield 
metabolically functional adipocytes with the highest amount of AdipoRed with the most 
clinically relevant glucose concentration will be applied to future studies regarding 
adipose tissue within the bioreactor systems described in Chapter 3.2.5. 
3.2.5 Bioreactor Inoculation 
The bioreactors are prototyped by Stem Cell Systems (Berlin, Germany) and 
contain three independent hollow fiber membrane systems, interwoven into repetitive 
subunits, forming a cell compartment that houses 8.0 × 10
7
 cells with a volume of 8 mL
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[Fig. 8].  The capillary network serves three functions: cell oxygenation/carbon dioxide 
removal, medium inflow, and medium outflow via countercurrent flow operation of two 
independent membrane systems.  As a result of interweaving and high performance mass 
exchange via counter-current medium flow operation, decentralized gas supply and 
medium exchange with low gradients is provided to the cultures.  The medium fiber 
membrane systems are comprised of polyethersulfone capillary systems (Membrana, 
Wuppertal, Germany) with a molecular weight cutoff of 400,000 g·mol
-1
 and gas is
supplied by hydrophobic multi-laminate hollow fiber membrane systems (MHF; 
Mitsubishi, Tokyo, Japan).  
A total of four bioreactor experiments were performed: two bioreactors cultured 
with ASCs in media at a “healthy physiological” condition, and two bioreactors cultured 
with ASCs in media at a “type II diabetic physiological” condition.  Bioreactor 
sterilization was performed with ethylene oxide gas and degassed with air.  Before cells 
were introduced into the system, a continuous phosphate buffered solution flush was run 
within the bioreactor for 72 hours, followed by priming with DMEM/F12 media flush for 
24 hours prior to inoculation.  Cell suspensions of 8.0 × 10
7
 total cells per bioreactor
were inoculated and cultured throughout a time period of six weeks.  The cell 
compartments were continuously perfused with culture media through the 
polyethersulfone hollow fiber bundles at a feed rate of 4 mL·hr
-1 
in combination with a
recirculation loop at a rate of 20 mL·min
-1
.  Waste medium was removed from the circuit
at 4 mL·hr
-1
.  The flows of compressed air and carbon dioxide in the gas compartment
were maintained at 20 mL·min
-1
.  Partial pressures of oxygen, carbon dioxide, and
acid/base status within the bioreactor were measured daily and the carbon dioxide content 
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was adjusted throughout culture time to maintain the medium pH within the range of 
7.35-7.45. 
3.2.6 Ex Vivo Human ASC Culture 
Human adult adipose stem cells were inoculated into the bioreactor cell 
compartments via a suspension of 8.0 x 10
7 
cells per mL of medium.  Cell passages at
time of inoculation for each experiment were either passage 2 or 5 and are described in 
Table 6.  Upon completion of a twenty-two day expansion period of the ASCs within the 
bioreactor cell compartment by perfusion of ASC plating media (DMEM/F12 as 
described above), to initiate three-dimensional adipogenic differentiation, the feed media 
was changed for the following seventeen days to adipogenic media containing 
DMEM/F12, HEPES, biotin, pantothenate, human insulin, dexamethasone, 3-isobutyl-1-
methylxanthine (IBMX), PPAR-γ agonist, and antibiotics (ZenBio, Research Triangle 
Park, NC, USA).  Adipogenic differentiation media was diluted with DMEM containing 
no glucose to either 20% in two reactors or 35% in two reactors to represent “healthy” or 
“type II diabetic” environments, respectively.  Adipocytes were maintained for seven 
days with feed media containing DMEM/F12, HEPES, fetal bovine serum, biotin, 
pantothenate, human insulin, dexamethasone, and antibiotics.  Maintenance media was 
diluted with no-glucose DMEM to either 35% or 50% to represent “healthy” or “type II 
diabetic” environments, respectively.  Next, the “healthy” bioreactor cultures were 
exposed to 30 μM C2-ceramide stimulation for sixteen days while the “type II diabetic” 
bioreactors continued the same treatment as during the previous seven-day maintenance 
period.  Finally, as a “recovery” period, all four bioreactor cultures were once again 
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influenced by the same feed medium experienced in the initial maintenance period (either 
a 35 or 50% dilution).  Cells were not further passaged within the bioreactor; rather, cell 
fate was influenced by changes in culture medium. 
In parallel, ASCs in a two-dimensional control group were cultured in 175 cm
2
tissue culture flasks with ASC plating medium containing 10% v/v fetal bovine serum 
and 1% v/v penicillin/streptomycin, plated, and stored at 37 °C at 5% CO2.  2D control 
ASCs were cultured for three weeks, with static media changes every other day and 
passaged at 80% confluency.   
Table 6. Patient age, gender and BMI at time of ASC isolation used for bioreactors in 
Specific Aim 2. 
3.2.7 Ex Vivo Metabolic Activity Analysis 
Glucose production and consumption of the cells throughout culture within the 
bioreactors was assessed under a dynamic open-circuit system.  A sampling volume of 2 
mL was taken daily via a luer-lock sample port; glucose and lactate dehydrogenase levels 
measured (YSI 2300 STATE Plus Glucose & Lactate Analyzer; YSI Life Sciences, 
Bioreactor # Patient Age Gender BMI C2-cer 
Treatment? 
Patient # Cell 
Passage # 
1 66 Female 38.4 Yes 5 2 
2 66 Female 38.4 No 5 2 
3 61 Female 30.7 Yes 6 5 
4 61 Female 30.7 No 6 5 
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Yellow Springs, OH, USA; Quantichrom Lactate Dehydrogenase Kit; BioAssay Systems, 
Hayward, CA, USA).  
Glucose production/consumption rates of the cells were determined by a 
previously established protocol considering various parameters including measured 
glucose concentration within the recirculation sample, total system volume, baseline 
medium concentrations, flow rate of nutrients through the system, and time points of 
measurements [161-165, equations 2 and 3 Chapter 2.2.4.].  
3.2.8 Immunohistochemistry and Histology 
Upon termination of each bioreactor culture, tissue/fiber samples were extracted 
from the bioreactors and placed in 10% w/v buffered formalin (Thermo Scientific) and 
stored at 4 °C in the formalin for fixed histology samples.  Samples were stained with 
AdipoRed Assay Reagent to analyze lipid inclusion (Lonza, Walkersville, MD, USA).  
Samples were protected from light and incubated at room temperature with AdipoRed 
staining dilutions according to Lonza protocol for 40 minutes or with FABP4 antibody 
(Abcam, San Francisco, CA, USA), then exposed to DAPI (0.6 μg/mL, Invitrogen) and 
AlexaFluor 488 Phalloidin (6.6 μM, Invitrogen) to stain for nuclei and F-actin, 
respectively, for 10 minutes at room temperature.  Immunofluorescence was captured 
from an Olympus Fluoview 1000 Upright Confocal Microscope (Olympus America, 
Melville, NY, USA).  
Samples not used for immunofluorescence or SEM were paraffin embedded, 
stained with haematoxylin & eosin and Masson’s Trichrome, and imaged under bright 
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field microscopy of an Olympus Provis Light Microscope (Olympus America) for 
architectural assessment and to determine matrix formation.  
3.2.9 Scanning Electron Microscopy 
Bioreactor explants stored at 4 °C in formalin were air dried and placed onto 
metal stubs covered in double-sided copper tape.  The fibers were then gold-sputtered to 
a density of 3.5 mm from Cressington 108 auto sputter-coater (Cressington, Watford, 
UK) and imaged with a JEM-6330f Scanning Electron Microscope (Jeol, Peabody, MA, 
USA).  Scope was operated at 5kV acceleration.  
3.2.10 Statistical Methods 
Results are presented as mean ± standard deviation.  One-way ANOVA was 
performed to assess differences in metabolic activity, lipid accumulation, and nuclei 
expression between treatment groups.  Tukey HSD or Games-Howell post-hoc testing 
identified differences between the groups.  All data were found to be normally distributed 
and variances were homogenous.  Statistical significance is determined at p-values less 
than 0.05. 
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3.3 RESULTS AND DISCUSSION 
3.3.1 In Vitro Metabolic Activity
The glucose levels found to be most physiologically relevant were established in 
differentiation media diluted to concentrations of 35% (164 mg/dL) and 20% (96.3 
mg/dL) to represent blood glucose levels observed in patients with and without type II 
diabetes mellitus, respectively [Figure 17].  In the separate study featuring C2-ceramide 
and FFA exposure, elevated daily glucose measurements confirmed inhibited glucose 
uptake by the adipocytes exposed to FFAs and C2-ceramide and are exhibited in Figure 
15, with 25 μM C2-ceramide without FFAs proving the most optimal for a type II 
diabetes mellitus glucose concentration [Fig. 18]. While lactate dehydrogenase levels 
increased slightly after addition of FFA supplement and C2-ceramide, indicating initial 
cell death, no outstanding presence of LDH was noted subsequently.  
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Figure 17. Glucose levels within the culture wells.  Differentiation media included biotin, 
gluatmin, transferrin, pantothenate, insulin, dexamethasone, T3, ciglitazone, IBMX, DMEM, 
antibiotics, antifungal, and was diluted with glucose-free DMEM. 100 µL samples taken daily 
and measured via YSI 2300 Stat Plus glucose and lactate analyzer. 
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3.3.2 Adipogenesis and Nuclei Characterization & Quantification  
AdipoRed quantification was higher in all groups treated with adipocyte 
differentiation media than in the negative control group, which received ASC plating 
DMEM-based media only.  ASCs receiving differentiation media of pure ZenBio or 
dilutions of 100%, 50%, and 35% fluoresced higher amounts of AdipoRed, indicating 
higher adipocyte differentiation over seven days than ASCs exposed to 30%, 25%, and 
20%, or ASC plating media only [Fig. 19].  No statistical difference in nuclei 
Figure 18. Glucose levels within the culture wells of ASCs differentiated and maintained 
with stimulation by either C2-ceramide, FFAs, both, or none.  C2-ceramide and FFA 
exposure inhibited glucose uptake as noted by increase in glucose concentration within the 
culture well samples over time. 100 µL samples taken daily and measured via YSI 2300 Stat Plus 
glucose and lactate analyzer.  
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quantification was observed between any groups, indicating dilutions had no effect on 
cell number after 7 days. 
AdipoRed quantification was higher in groups treated with both C2-cermide and 
FFAs than groups treated with C2-ceramide, FFAs alone, or the negative control group, 
which received ASC plating DMEM-based media only [Fig. 20].  AdipoRed 
Figure 19. AdipoRed (lipid accumulation) and DAPI (nuclei) fluorescence quantification of ASCs 
after 7 days of exposure to differentiation medium at physiologically relevant glucose concentrations 
ranging from healthy to diabetic to plating media controls), established by varying nutrient media 
dilutions.  (*, @, +, $ = p < 0.05; N=11; one-way ANOVA, Tukey’s post-hoc testing) 
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quantification was indirectly proportionate to C2-ceramide dose when cells were not 
exposed to both C2-ceramide and FFA.  
AdipoRed and DAPI fluorescence of ASCs exposed to various differentiation 
media dilutions were also imaged and are displayed in Figure 21.  Correlating with the 
quantitative representation of differentiation, qualitative differences in differentiation 
appeared between the 30% and 35% benchmarks [Fig 21].  
Figure 20. Lipid accumulation and DAPI (nuclei) quantification of ASCs after 7 days of 
exposure to differentiation medium at physiologically relevant glucose concentrations during 
exposure to C2-ceramide and free fatty acids.  (*, @, +, $, # = p < 0.05; N=8; one-way 
ANOVA, Games-Howell post-hoc testing). 
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AdipoRed and DAPI fluorescence of ASCs differentiated and metabolically tested 
with C2-ceramide and/or FFA were also imaged and are shown in Figure 22.  Figure 22F 
confirms positive AdipoRed and DAPI fluorescence of ASCs when differentiated at 35% 
in-house differentiation media then exposed to 25 μM C2-ceramide.   
Figure 21. AdipoRed (red) and DAPI (blue) of ASCs exposed to the Adipose Stem Cell 
Center’s in-house differentiation medium at various dilutions over a 7-day period. A) 100% 
ZenBio differentiation medium, B) 100% in-house differentiation, C) 50% dilution, D) 35% 
dilution, E) 30% dilution, F) 25% dilution, G) 20% dilution, H) 10% dilution, I) 5% dilution, J) 
2.5% dilution, K) 1% dilution, and L) ASC plating medium only.  ZenBio serves as positive 
control differentiation medium, ASC plating medium negative control.  Scale bar = 50 μm. 
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3.3.3 Ex Vivo Metabolic Activity 
Figures 23 and 24 represent average glucose and lactate production within the 
bioreactors of the cells and tissue using aforementioned protocol during ASC expansion 
(days 0-22), ASC differentiation into adipocytes (days 23-40), and adipocyte 
maintenance (days 41-70) within all four bioreactors, where solid squares signify glucose 
Figure 22. AdipoRed and DAPI of ASCs exposed to C2-ceramide and/or Free Fatty Acids over a 
7-day period, differentiated at either 35% or 20% in-house differentiation medium. A) 150µM C2-
ceramide + FFA; B) 100µM C2-ceramide + FFA; C) 25 µM C2-ceramide + FFA; D) 150µM C2-
ceramide; E) 100µM C2-ceramide; F) 25 µM C2-ceramide; G & H) FFA only; I) Maintenance 
media only (no C2-ceramide/FFA); J) 20% in-house diff media; K) ASM plating media only. Scale 
bar = 50 μm.  Red = AdipoRed, Blue = DAPI. 
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production/consumption of cells receiving a “healthy physiological” treatment and empty 
squares denote cells receiving the “type II diabetic” treatments.  The cultures receiving 
the media containing the healthy glucose concentration were treated with C2-ceramide at 
day 48 with the hypothesis that the sphingolipid would inhibit insulin-stimulated glucose 
uptake by the adipocytes.  Days 64-70, the cultures exposed to the C2-ceramide were 
under a “recovery” period, during which the 35% diluted maintenance medium was re-
introduced to the system until experiment termination at day 70.  
Throughout bioreactor culture experimentation, average glucose 
production/consumption of the ASCs in the “healthy physiological” cultures appeared to 
remain steady, with the exception of two major outliers in the differentiation phase, 
which were caused by a disruption in the media feeding, a human error.   A noticeably 
large peak at the beginning of the C2-ceramide stimulation was observed; however, an 
elevated glucose level to indicate a hindered GLUT4 translocation within the adipocyte 
cell membranes and, thereby, an obstructed insulin-simulated glucose uptake was not 
continuous throughout the C2-ceraide stimulation phase.  Meanwhile, the cultures 
influenced by feed media containing a glucose concentration comparable to patients with 
type II diabetes experienced a slightly more dynamic fluctuation in glucose consumption 
and production [Figure 23]. 
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Figure 24 depicts lactate consumption and production throughout the 70-day 
bioreactor culture of both experimental groups, where solid blocks represent metabolic 
activity of cultures undergoing a “healthy physiological” level of glucose concentration 
plus the C2-ceramide exposure period, and empty blocks display cultures fed with media 
containing glucose concentration at levels similar to those of patients with type II 
diabetes.  No outstanding difference between the two groups was observed throughout 
culture.  However, dynamic lactate production displayed at periods adjacent to medium 
Figure 23. Metabolic activity. Average glucose production/consumption trends of two 
bioreactors seeded with ASCs, differentiated with treatments of diluted medium to establish a 
healthy physiological glucose level (solid squares), and two bioreactors seeded with ASCs  
differentiated with treatments of diluted medium to establish a type II diabetic glucose level 
(empty squares) over 70 days of culture.   
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period changes may be attributed to ASCs and adipocytes preparing for differentiation or 
maintenance through storage or release of lactate.  
3.3.4 Immunohistochemistry and Histology 
Imaging results of the tissue generated within the bioreactors are shown in Figures 
25-26.  Macroscopic tissue formation was observed in and around the hollow fiber
membranes upon bioreactor disassembly [Figures 25 and 26].  Regarding both groups of 
adipose tissue – that differentiated from ASCs under healthy glucose conditions and that 
Figure 24. Metabolic activity. Average lactate glucose production/consumption trends of two 
bioreactors seeded with ASCs, differentiated with treatments of diluted medium to establish a 
healthy physiological glucose level (solid squares), and two bioreactors seeded with ASCs  
differentiated with treatments of diluted medium to establish a type II diabetic glucose level (empty 
squares) over 70 days of culture.   
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differentiation from ASCs under conditions similar to glucose conditions of diabetic 
patients – histological analyses revealed closely associated adipocytes throughout all 
bioreactors.  Confocal fluorescent imaging demonstrated AdipoRed lipid formation and 
FABP4 expression after 70 days of culture within the dynamic perfusion systems, while 
DAPI and AlexaFluor 488 Phalloidin highlight nuclei and F-actin, respectively [Fig. 25]. 
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Figure 25. Immunohistochemistry. End-point 70 days, (A, C) FABP4/DAPI/Phalloidin 
or (B, D) AdipoRed/DAPI/Phalloidin immunohistochemistry from bioreactors containing 
ASCs differentiated into adipocytes and maintained at (A, B) healthy physiological 
glucose concentrations followed by C2-ceramide exposure or at (C, D) physiological type 
II diabetes mellitus glucose concentrations.  Scale bar = 50 μm, red = AdipoRed, green = 




Figure 26. Histology. End-point 70 days, (A, C) H&E or (B, D) Masson’s Trichrome from 
bioreactors containing ASCs differentiated into adipocytes and maintained at (A, B) 
healthy physiological glucose concentrations followed by C2-ceramide exposure or at (C, 
D) physiological type II diabetes mellitus glucose concentrations. Solid arrows indicate 
adipose architecture, dashed arrows indicate bioreactor fiber.  Scale bar = 100 μm. 
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3.3.5 Scanning Electron Microscopy 
SEM images of the samples removed from all bioreactors reveal cell growth on 
and among the hollow fibers with no extreme difference between the two experimental 
groups [Fig. 27]. 
3.4 CONCLUSIONS 
Adult human ASCs isolated from healthy, non-diabetic patients, were 
differentiated into adipocytes as treated by culture medium consisting of various levels of 
glucose and, in a second in vitro study, adipocytes were exposed to a culture environment 
to simulate that of a type II diabetic patient.  Once physiologically similar glucose levels 
Figure 27. Scanning Electron Micrographs. Scanning Electron Microscopy (SEM) images of 
adipocytes on fibers extracted from bioreactors after 70 days of culture inoculated with ASCs 
differentiated and maintained  (A) healthy physiological glucose concentrations followed by 
C2-ceramide exposure or at (B) physiological type II diabetes mellitus glucose concentrations.  
Scale bar = 100 μm. 
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(20% dilution to represent glucose concentration similar to a non-diabetic adult and 35% 
dilution to represent glucose concentration of an adult with type II diabetes mellitus) 
were determined within adipocyte differentiation-inducing medium, a type II diabetic 
environment was created by addition of FFA and C2-Ceramide, inhibiting glucose 
transport.  No major cell death was observed through days 2-7 of adipocyte maintenance, 
during which FFA and 2-Ceramide were included, indicating low levels of cell toxicity.  
A concentration of 35 μM C2-ceramide without FFA was found to yield the most optimal 
hindered glucose uptake by the differentiated ASCs. The presented work lays the 
groundwork necessary for future application of the developed protocol into a hollow 
fiber-based bioreactor that allows long-term maintenance of adipose tissue to establish a 
physiologically relevant, type II diabetic-like environment. 
Human adipose-derived stem cells derived from female adults without type II 
diabetes mellitus were cultured within hollow fiber-based membrane, three-dimensional, 
dynamic perfusion bioreactors for 70 days and metabolic behaviors were assessed.  
Masson’s Trichrome, H&E, AdipoRed, and FABP4 images of the functional adipocytes 
show no major difference between adipose tissue generated in cultures with glucose 
levels at healthy or diabetic concentrations.  The lack of elevated glucose levels during 
C2-ceramide stimulation may be due to a scale-up issue, or a downstream differentiation 
discrepancy between the study of Summers et al. [123, 181], plus the in vitro studies 
explained in Chapter 3 compared to ex vivo scenarios of mature adipocytes exhibited in 
the bioreactor systems. The presented work provides a first step towards an engineered 
model necessary to the study of anti-diabetic drug therapy ex vivo in addition to a 
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platform for three-dimensional perfusion and long-term maintenance of functional 
adipocytes. 
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4.0 APPLICATION OF A DECELLULARIZED ADIPOSE EXTRACELLULAR 
MATRIX HYDROGEL TO ENHANCE ADIPOSE TISSUE GROWTH 
HOMOGENEITY WITHIN A HOLLOW FIBER-BASED, THREE-
DIMENSIONAL, DYNAMIC PERFUSION BIOREACTOR 
4.1 INTRODUCTION
4.1.1 Decellularized Extracellular Matrix Materials 
Decellularization is a process commonly used in tissue engineering and 
regenerative medicine to isolate the extracellular matrix (ECM) of a tissue by removal of 
the inhabiting cells to serve as a scaffold for cell growth, differentiation, and tissue 
development [182-184].  Elimination of the native cells eliminates concerns of organ 
rejection and lifetimes of immunosuppression medications for patients.  
Decellularized tissue and organs have offered solutions to several regenerative 
preclinical applications, including skin grafting, cardiac tissue engineering, lung 
transplantation, and pancreatic engineering. Numerous methods have been proven to 
decellularize a variety of tissues, including combinations of mechanical [185-191], 
chemical [192-201], and enzymatic [202-210] methods.  Many studies have concluded 
that the methods by which the ECM biomaterial is prepared have a significant 
influence on the biochemical and structural properties of the resulting scaffold.   
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Biological scaffold materials composed of decellularized ECM have been 
considered as medicinal devices by regulatory bodies, such as the Food and Drug 
Administration.  With commercialization attempts at injectable and hydrogel forms of 
ECM products, this form of ECM biomedical products will be classified and regulated as 
a biologic.   
In a 2009 study by Gilbert et al., DNA content and fragment length were 
determined in both laboratory-produced and commercially available ECM scaffold 
materials [211].  The team examined six commercially available ECM scaffolds: two 
from porcine small intestine (Oasis – Cook Biotech, Inc. and Restore – DePuy 
Orthopaedics), Acell Vet (Acell, Inc.) originating form porcine urinary bladder, Zimmer 
Collagen Repair Patch (Zimmer, Inc.) originating from porcine dermis, and two from 
human dermis (Alloderm – Lifecell, corp. and GraftJacket – Wright Medical 
Technology).  The three laboratory-produced ECM scaffolds were derived from porcine 
small intestine, porcine urinary bladder, and porcine liver.  Through DAPI, H&E, DNA 
quantification through PicoGreen DNA assay, and fragment length analysis, results 
showed that the majority of DNA is removed from ECM devices, but small amounts 
remain in most tested materials (with most fragments less than 300 base pairs long) 
[211].  Despite DNA presence in many of the commercially available ECM products 
studied, their clinical efficacy has proven successful [212-225].  It is mentioned that 
complete removal of all cellular contents is likely impossible due to the manner in which 
cells are embedded within tissue, especially dense tissues such as the dermis, in addition 
to intracellular cytoplasmic proteins and membrane components being retained in the 
scaffold materials during the processing steps [211].   
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Host response following surgical implantation of biological surgical ECM devices 
may vary from poor to excellent [226-230].  The diverse range in outcomes is associated 
with factors related to device manufacturing methods and the type and intensity of the 
innate immune response elicited by the final product [230].  Three factors known to 
influence bioscaffold remodeling include efficacy of decellularization [231-243], use of 
chemical crosslinking agents [244-252], and age of the source tissue from which the 
ECM is collected [253-257].   According to Dr. Stephen Badylak, two categories of 
bioscaffold remodeling include constructive and proinflammatory remodeling.  
Constructive remodeling of ECM scaffolds involves complete degradation of a 
degradable biomaterial and gradual replacement by anatomically appropriate and 
functional tissue.  This occurs when an ECM scaffold is prepared by methods through 
decellularization of the source tissue and avoidance of the use of chemical crosslinking 
methods for the resultant ECM product [230, 258].  Proinflammatory response to ECM 
scaffolds can consist of chronic inflammation when the material is used for inappropriate 
clinical applications and/or when the biomaterial was manufactured via methods that alter 
the native structure and composition of the matrix [230].  
4.1.2 Decellularized Adipose Tissue ECM 
Over the past decade, adipose tissue engineering has quickly escalated with 
attention to the reconstructive properties and advantages innate to adipose tissue [4, 55-
63].  While some preclinical research has focused on three-dimensional scaffolds as 
structural support for promoting adipogenesis and volume retention, an injectable option 
may prove to be more clinically relevant and would share more similar physical 
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properties to lipoaspirate than a synthetic or biopolymer scaffold.  Most commercially 
available soft tissue fillers comprise of collagen, hyaluronic acid, hydroxyapatite, or 
polylactic acid, and many studies are currently investigating injectable synthetic and 
natural polymers for adipose tissue engineering. A few groups have evaluated ASC 
proliferation, neovascularization, and adipogenesis under the influence of human adipose 
tissue either in a lyophilized [259], powder form [260], or as a decellularized, delipidized 
ECM hydrogel [260, 261].   
4.1.3 Chapter Aims 
The studies presented in Chapter 4 describe Specific Aim 3 to further enhance the 
adipose tissue ex vivo by optimizing homogeneity within the bioreactor culture.  The 
work is driven by the hypothesis that inclusion of a decellularized adipose tissue 
extracellular matrix (ECM) hydrogel within the ex vivo bioreactor culture system will 
enhance ASC differentiation to the adipocyte lineage and improve adipose tissue 
homogeneity within the bioreactor.  
4.2 MATERIALS AND METHODS 
4.2.1 Decellularization of Adipose ECM 
Adipose tissue delipidization, decellularization, and gelation protocols were 
optimized influenced upon combinations of previous work reported in the literature [261, 
263].  Adipose tissue was harvested from the abdominal depot of non-diabetic female 
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patients undergoing elective plastic surgery at the University of Pittsburgh Medical 
Center in Pittsburgh, PA, USA.  Tissue was collected under a human studies exempt 
protocol approved by the University of Pittsburgh Institutional Review Board (IRB).  De-
identified specimens were obtained from discarded surgical tissue under an approved 
process that did not require subjects to provide written or verbal informed consent.  
Whole adipose tissue was run through a meat grinder (Demi 800 HP table top 
meat grinder) with first a coarse grinding plate then a fine grinding plate, centrifuged at 
1000 rpm (6449 x g) and 4 °C for 10 minutes.  Once the lipid layer is carefully removed 
via glass pipetting, the adipose layer was stirred with a 1:1 m/v ratio of 1-propanol for a 
series of 1.5, 20, 2, 1.5 hours, with a centrifugation, removal of supernatant and lipid, 
plus replenishing of 1-propanol at each change.  Following the 1-propanol washes was a 
series of EtOH washes of 100% for 30 minutes, 90% for 15 minutes, and 85%, 70%, 70% 
for 10 minutes, with a centrifugation and removal of supernatant between each step. 
For decellularization, adipose tissue was soaked and stirred for thirty hours in a 
1M NaCl solution, centrifuged with supernatant removed, then soaked and stirred in 
0.1% Triton X-100 for 72 hours.  After centrifugation and removal of supernatant, 1-
propanol and EtOH washes were repeated.  To disinfect, the adipose ECM was washed 
twice with DI water, centrifuged and supernatant removed, then soaked for no longer 
than 4 hours in 1% peracetic acid.  Solution was centrifuged, supernatant removed, 
washed with 10X PBS, centrifuged and supernatant removed, then washed with 1X PBS 
three times.  Decellularized adipose ECM was stored at 4 °C in 1X PBS until ready to 
use. 
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To form a hydrogel, decellularized adipose ECM was lyophilized (Labconco, 
Kansas City, MO, USA), grinded via mortar and pestle, then sifted by a Thomas Wiley 
Mill (Thomas Scientific, Swedesboro, NJ, USA).  Decellularized adipose ECM was 
stored at -20 °C until ready for digestion.  To digest the decellularized adipose ECM 
powder, 1 mg pepsin per 10 mg adipose ECM in 0.1M HCl was stirred for 48 hours. 
Hydrogel formed at 37 °C within 30 minutes and was sterilized via 20 minutes of UV 
sterilization.     
4.2.2 Characterization of Adipose ECM 
4.2.2.1  Histology 
Decellularized adipose ECM was fixed in 10% buffered formalin, processed, 
paraffin embedded, then sectioned at 6 μm-thick slices.  Samples were assessed by 
staining with H&E and imaged on an Olympus Provis Light Microscope (Olympus 
America, Melville, NY, USA).  
Non-paraffin embedded samples were analyzed via Scanning Electron 
Microscopy (SEM), samples were air dried and placed onto metal stubs covered in 
double-sided copper tape.  The samples were then gold-sputtered to a density of 3.5 mm 
from Cressington 108 auto sputter-coater (Cressington, Watford, UK) and imaged with a 
JEM-6330f Scanning Electron Microscope (Jeol, Peabody, MA, USA).  Scope was 
operated at 5kV acceleration.  
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To evaluate nuclei presence, a sample of decellularized adipose ECM and a native 
adipose sample were stained with DAPI and imaged on an Olympus Provis Light 
Microscope. 
4.2.2.2  Immunohistochemistry 
To test antibody specificity of the decellularized adipose ECM, paraffin 
embedded samples were rehydrated, antigens unmasked via a 10 mM sodium citrate 
buffer pH 6.0 for 40 minutes at 97.0 ±1 °C.   Slides were blocked for engodgenous 
peroxidase activity with 3% H2O2 for 20 minutes, then blocked with an Avidin/Biotin 
solution (Vector Laboratories, Burlingame, CA, USA) plus an antibody diluent 
containing SuperBlock T20 (Thermo Fisher), goat serum, and BSA in addition to the 
primary antibody of choice overnight at 4 °C.  Biotin-conjugated secondary antibody 
were incubated on samples for 30 minutes and exposed via DAB chromagen.  Slides 
were counterstained with hematoxylin, dehydrated, and coverslipped with permount then 
imagined on an Olympus Provis Light Microscope. 
4.2.2.3  In vitro cell viability 
Before inoculating valuable bioreactor systems with a novel biological hydrogel, 
cell viability must be evaluated.  ASCs were seeded at 10,000 cells per well within a 96-
well plate either with or without the decellularized adipose ECM gel, and were either 
stimulated by differentiation media or maintained with ASC plating media at studied at 1 
or 7 days.  Cell feed medium was changed every other day and cells stored at 37 °C at 5% 
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CO2.  At 1 and 7 days, ASCs were fixed with 4% paraformaldehyde for 30 minutes, 
washed with 1X PBS and quantitatively examined via Live/Dead staining.  
4.2.3 ASC Isolation 
Adipose tissue was harvested from the abdominal depot of a non-diabetic female 
patient (58 years old, body mass index (BMI) of 36.0) undergoing elective plastic surgery 
at the University of Pittsburgh Medical Center in Pittsburgh, PA, USA.  Tissue was 
collected under a human studies exempt protocol approved by the University of 
Pittsburgh Institutional Review Board (IRB). De-identified specimens were obtained 
from discarded surgical tissue under an approved process that did not require subjects to 
provide written or verbal informed consent.  Donors were not pre-diabetic and did not 
have insulin resistance at time of adipose tissue harvesting.   
Abdominal adipose tissue was placed in 50 mL centrifuge tubes at 10 g per tube 
and soaked in 1 mg·mL
-1
 of freshly prepared collagenase (Type II collagenase, 
Worthington Biochemical Product Catalog; Lakewood, NJ, USA).  The tissue was finely 
minced, vortexed, and shaken at 37 °C for 35 minutes until a fatty supernatant layer 
became apparent.  Tubes were again vortexed and filtered through double-layered gauze 
(J&J Steri-Pad Gauze Pads; New Brunswick, NJ, USA) into sterile 50 mL centrifuge 
tubes.  Digested specimens were then centrifuged at 1000 rpm (6449 x g), 4 °C for 10 
minutes, fatty layers aspirated, and resulting pellets suspended in erythrocyte lysing 
buffer.  The solution was once again centrifuged at 1000 rpm (6449 x g), 4 °C for 10 
minutes and the pellet, containing the stromal vascular fraction, was resuspended in 
Dulbecco’s Modified Eagle’s Medium (DMEM/F12) with 10% v/v fetal bovine serum 
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and 1% v/v penicillin/streptomycin, plated, and stored at 37 °C at 5% CO2.  Cells were 
expanded in two dimensions using growth medium with low serum (Promocell 
Preadipocyte Growth Medium, Heidelberg, Germany), passaged at confluency, and 
characterized as previously described by our laboratory [56].  
4.2.4 Bioreactor Inoculation 
The bioreactors are prototyped by Stem Cell Systems (Berlin, Germany) and 
contain three independent hollow fiber membrane systems, interwoven into repetitive 
subunits, forming a cell compartment that houses 8.0 × 10
7
 cells with a volume of 8 mL 
[Fig. 8].  The capillary network serves three functions: cell oxygenation/carbon dioxide 
removal, medium inflow, and medium outflow via countercurrent flow operation of two 
independent membrane systems.  As a result of interweaving and high performance mass 
exchange via counter-current medium flow operation, decentralized gas supply and 
medium exchange with low gradients is provided to the cultures.  The medium fiber 
membrane systems are made of polyethersulfone capillary systems (Membrana, 
Wuppertal, Germany) with a molecular weight cutoff of 400,000 g·mol
-1
 and gas is 
supplied by hydrophobic multi-laminate hollow fiber membrane systems (MHF; 
Mitsubishi, Tokyo, Japan).  
Table 7 describes the experimental design of Specific Aim 3.  A total of six 
bioreactor experiments were performed: three bioreactors received ASCs in combination 
with the decellularized adipose ECM at inoculation, and three bioreactors received ASCs 
in media suspension, with no ECM addition at inoculation.  Bioreactor sterilization was 
performed with ethylene oxide gas and degassed with air.  Before cells were introduced 
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into the system, a continuous phosphate buffered solution flush was run within the 
bioreactor for 72 hours, followed by priming with DMEM/F12 media flush for 24 hours 
prior to inoculation.  Cell suspensions of 4.5 × 10
7
 total cells per bioreactor were
inoculated and cultured throughout a time period of five weeks.  The cell compartments 
were continuously perfused with culture media through the polyethersulfone hollow fiber 
bundles at a feed rate of 4 mL·hr
-1 
in combination with a recirculation loop at a rate of 20
mL·min
-1
.  Waste medium was removed from the circuit at 4 mL·hr
-1
.  The flows of
compressed air and carbon dioxide in the gas compartment were maintained at 20 
mL·min
-1
.  Partial pressures of oxygen, carbon dioxide, and acid/base status within the
bioreactor were measured daily and the carbon dioxide content was adjusted throughout 
culture time to maintain the medium pH within the range of 7.35-7.45. 
Table 7. Experimental design of Specific Aim 3. 







4.2.5 Cell Culture 
Cells were inoculated into the bioreactor cell compartments via a suspension of 
4.5 x 10
7 
cells per mL of medium and/or adipose ECM [Fig. 27].  Cell passage at time of 
inoculation was at passage 4.  Upon completion of a twenty-one day expansion period of 
the ASCs within the bioreactor cell compartment by perfusion of ASC plating media 
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(DMEM/F12 as described above), to initiate three-dimensional adipogenic 
differentiation, the feed media was changed for the following fourteen days to adipogenic 
media containing DMEM/F12, HEPES, biotin, pantothenate, human insulin, 
dexamethasone, 3-isobutyl-1-methylxanthine (IBMX), PPAR-γ agonist, and antibiotics 
(ZenBio, Research Triangle Park, NC, USA). Adipocytes were maintained for seven days 
with feed media containing DMEM/F12, HEPES, fetal bovine serum, biotin, 
pantothenate, human insulin, dexamethasone, and antibiotics.Cells were not further 
passaged within the bioreactor, rather, cell fate was influenced by changes in culture 
medium. 
In parallel, ASCs in a two-dimensional control group were cultured in 175 cm
2
tissue culture flasks with ASC plating medium containing 10% v/v fetal bovine serum 
and 1% v/v penicillin/streptomycin, plated, and stored at 37 °C at 5% CO2.  2D control 
ASCs were cultured for forty-four days with static media changes every other day and 
passaged at 80% confluency.   
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Figure 28. Bioreactor setup for Specific Aim 3.  Six bioreactors connected to three perfusion 
pumps set to circulate feed media at a 4.5 mL/hr rate.  Feed media is stored at 4 °C and is 
highlighted in the schematic along with the waste buckets, which are discarded when full. 
Bioreactors 1, 3, and 5 received a decellularized adipose ECM hydrogel upon bioreactor 
inoculation with ASCs, while bioreactors 2, 4, and 6 were inoculated with ASCs only.   
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4.2.6 Metabolic Activity Analysis 
Glucose production rate throughout culture was assessed under a dynamic open-
circuit system.  A sampling volume of 2 mL was taken daily via a luer-lock sample port; 
glucose and lactate dehydrogenase levels measured (YSI 2300 STATE Plus Glucose & 
Lactate Analyzer; YSI Life Sciences, Yellow Springs, OH, USA; Quantichrom Lactate 
Dehydrogenase Kit; BioAssay Systems, Hayward, CA, USA).  
Glucose production/consumption rates of the cells were determined by a 
previously established protocol considering various parameters including measured 
glucose concentration within the recirculation sample, total system volume, baseline 
medium concentrations, flow rate of nutrients through the system, and time points of 
measurements [161-165, Eqns 2 and 3 Chapter 2.2.4.].  
4.2.7 Tumor-Necrosis Factor-a Functional Testing 
After seven days of maintenance, adipocytes within all six bioreactor cultures 
underwent exposure to 10 ng·mL
-1
 direct injection of tumor necrosis factor (TNF)-α 
(Roche Applied Sciences, San Francisco, CA, USA) intended to inhibit glucose uptake 
by the adipocytes.  TNF-α exposure lasted for 24 hours and glucose production was 
measured every 30 minutes.  Feed inlet and waste outlet flow rates were set to 10 mL·hr
-1
to ensure that the entire circuit volume was replaced every hour.  Throughout TNF-α 
exposure, media containing 10 ng·mL
-1
 dosage of TNF-α and no insulin was delivered to 
the tissue with intention of hindering glucose consumption of the adipocytes.  
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Once glucose consumption/production had stabilized after 24 hours of TNF-α 
delivery, all six bioreactors were stimulated with human insulin as a “recovery” (Sigma-
Aldrich, St. Louis, MO, USA) by a 5 μM direct injection in addition to delivering feed 
medium containing insulin to maintain a steady influx of insulin for an 8-hour period.   
After the 8-hour stimulation period, feed medium was returned to non-insulin containing 
medium and glucose consumption measurements were continued for another 20 hours to 
confirm adipocyte metabolism had returned to baseline before bioreactor disassembly. 
4.2.8 Immunohistochemistry and Histology 
Upon termination of each bioreactor culture, tissue/fiber samples were extracted 
from the bioreactors and placed in 10% w/v buffered formalin (Thermo Scientific) and 
stored at 4 °C in the formalin for fixed histology samples.  Samples were stained with 
AdipoRed Assay Reagent to analyze lipid inclusion (Lonza, Walkersville, MD, USA).  
Samples were protected from light and incubated at room temperature with AdipoRed 
staining dilutions according to Lonza protocol for 40 minutes, then exposed to DAPI (0.6 
μg/mL, Invitrogen) and AlexaFluor 488 Phalloidin (6.6 μM, Invitrogen) to stain for 
nuclei and F-actin, respectively, for 10 minutes at room temperature.  
Immunofluorescence was captured from an Olympus Fluoview 1000 Upright Confocal 
Microscope (Olympus America, Melville, NY, USA).  
Additionally, samples were paraffin embedded, stained with Masson’s 
Trichromeand imaged under bright field microscopy of an Olympus Provis Light 
Microscope (Olympus America) for architectural assessment, to determine matrix 
formation, and to verify human tissue growth.  
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To test antibody specificity within the bioreactor culture samples, paraffin 
embedded samples were rehydrated, antigens unmasked via a 10 mM sodium citrate 
buffer pH 6.0 for 40 minutes at 97.0 ±1 °C.   Slides were blocked for endogenous 
peroxidase activity with 3% H2O2 for 20 minutes, then blocked with an Avidin/Biotin 
solution (Vector Laboratories, Burlingame, CA, USA) plus an antibody diluent 
containing SuperBlock T20 (Thermo Fisher), goat serum, and BSA in addition to the 
primary antibody of choice overnight at 4 °C.  Biotin-conjugated secondary antibody 
were incubated on samples for 30 minutes and exposed via DAB chromagen.  Slides 
were counterstained with haematoxylin, dehydrated, and coverslipped with permount.     
4.2.9 Statistical Methods 
Results are presented as mean ± standard deviation.  Unpaired, two-tailed t-tests 
were performed to assess differences in metabolic activity between treatment groups. All 
data were found to be normally distributed and variances were homogenous.  Statistical 
significance is determined at p-values less than 0.05. 
4.3 RESULTS AND DISCUSSION 
4.3.1 Decellularized Adipose ECM Characterization 
4.3.1.1 Histology 
When stained with H&E, the architectural properties of the adipose ECM 
appeared vastly different from that of native whole adipose tissue [Fig. 29].  
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Qualitatively, adipocyte architecture was not observed in the decellularized adipose 
ECM, indicating delipidization.   Furthermore, nuclei visible in the native whole adpose 
tissue were not apparent in the decellularized sample, suggesting successful 
decellularization.  
Observation via scanning electron microscopy reveals the decellularized adipose 
ECM displayed the architecture of apparent vacuoles, approximately 100 μm in which 
adipocytes may have existed before delipidization [Fig. 30].  The porous nature of the 
remaining matrix encourages the underlying hypothesis of Specific Aim 3 that 
incorporation into the bioreactor system will enhance adipogenesis and proliferation of 
tissue ex vivo. 
Figure 29. H&E staining of A) native adult human whole fat tissue and B) decellularized adipose 
ECM. Scale bar = 100 μm. 
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Assessing the decellularization of the adipose tissue with DAPI fluorescence, it is 
noted that, compared to native whole adipose tissue (Fig. 31B), the decellularized adipose 
ECM exhibited in Figure 31A has comparatively less nuclei; however, some nuclei still 
remain.  
Figure 30.  Scanning electron microscopy of decellularized adipose ECM at increasing 
magnifications: A) 55X, scale = 100 μm; B) 200X, scale = 100 μm; C) 850X, scale = 10 μm. 
Figure 31.  Nucleic assessment of A) decellularized adipose ECM and B) human whole fat 
tissue. Scale bar = 200 μm. 
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4.3.1.2  Immunohistochemistry 
Collagens I, III, IV, and VI in addition to heparan sulfate proteoglycan (HSPG) 
and nidogen expression within the decellularized adipose ECM were studied and 
compared to native whole adipose tissue.  While Collagens I, III, and VI were highly 
expressed in the decellularized adipose ECM, collagen IV, HSPG and nidogen were 
expressed at a lower level; however, still expressed [Figs. 32 and 33, Table 8].  
Collagens I, III, and VI are typically found alongside one another and were both 
expressed in the decellularized adipose ECM.  Collagen IV forms the basal lamina and 
the epithelium-secreted layer of the basement membrane. HSPG are the proteoglycan of 
heparan sulfate, attaching in close proximity to the cell surface or extracellular matrix 
proteins, and nidogen is a glycoprotein belonging to the basement membrane, connecting 
together networks formed by collagens and laminins.   
Expression of collagens I, III, IV, and VI in addition to HSPG and nidogen, it can 
be concluded that the ECM remains intact after the mechanical and chemical 
decellularization of the whole adipose tissue.    
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Figure 32. Immunohistochemical expression of A, B) collagen I; C, D) collagen 
III; and E, F) collagen IV, where the left column (A, C, E) is native human whole 
adipose tissue and the right column (B, D, F) is decellularized adipose ECM. 
Scale bar = 100 μm. 
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Figure 33. Immunohistochemical expression of collagen VI, HSPG, and 
nidogen, where the left column of is images of native human whole fat tissue and 
the right column is images of decellularized adipose ECM. Scale bar = 100 μm. 
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Table 8. Components in Native Human Whole Adipose Tissue and Decellularized ECM 
Biomaterial  






Cell guidance and migration, 
structure, and support 
Type I  
Type III  
Type IV  
Type VI  
Proteoglycans 
HSPG Binds growth factors  
Glycoproteins 
Nidogen 
Cell proliferation, migration, 
and attachment 
 
4.3.1.3  In vitro cell viability 
ASCs were cultured in 96 well plates either containing 100 μL of the 
decellularized adipose ECM hydrogel or no hydrogel.  The experiment was ended 24 
hours [Fig. 34] or 7 days after seeding [Fig. 35] and either exposed to adipocyte 
differentiation medium or simply ASC plating medium, which would not initiate 
differentiation.  At experiment termination, cell viability was quantified via Live/Dead 
staining which exposes live cells retaining the dye calcein fluorescing green, or dead cells 
allowing ethidium homodimer-1 (EthD1) through the damaged membranes and 
fluorescing red.  
At 24 hours, no significant difference was observed in cell death between groups.  
However, the groups without the adipose ECM hydrogel had a significantly higher 
number of live cells than the groups without adipose ECM hydrogel (p< 0.05, N=8, Fig. 
34).  
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At 7 days, no statistically significant difference in live cells was observed 
between any treatment groups, while there were differences in cell death between all 
groups (p< 0.05, N=8, Fig. 35).  Such a dramatic difference may be due to an effect of the 
adipose ECM hydrogel on the fluorescence quantification. 
Figure 34.  Cell viability after 24 hours of ASCs either cultured on adipose ECM 
hydrogel or directly on surface of 96 well plates. *, # p< 0.05, N=8, mean ± standard 
deviation. 
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Figure 35.  Cell viability after 7 days of ASCs either cultured on adipose ECM hydrogel or 
directly on surface of 96 well plates. * p< 0.05, N=8, mean ± standard deviation. 
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4.3.2 Metabolic Activity 
Figure 36 represents average glucose production and Figure 36 represents average 
lactate production within the bioreactors of the cells and tissue using aforementioned 
protocol during ASC expansion (days 0-21), ASC differentiation into adipocytes (days 
21-35), and adipocyte maintenance (days 35-43). Solid squares signify glucose
production/consumption of cells that were inoculated with decellularized adipose 
hydrogel and empty squares denote cells that were inoculated with feed medium only, no 
decellularized adipose hydrogel.   
Over the entire 43-day culture, glucose and lactate production of ASCs inoculated 
with decellularized adipose tissue hydrogel is no different within the bioreactor from 
glucose and lactate production of ASCs inoculated without decellularized adipose tissue 
hydrogel, up to a confidence interval of 95% with a N-value of 3.  However, as indicated 
in Figure 36, lactate production rate dropped to zero at day 3 of culture, indicating low 
cell proliferation rates.  The low lactate production continued throughout culture.  
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Figure 36. Metabolic activity. Glucose production/consumption (mg/hr) trends of three 
bioreactors seeded with ASCs supplemented with a decellularized adipose ECM hydrogel (filled 
squares) and three bioreactors seeded with ASCs only (empty squares) over 43 days of culture.  
Days 0-21 represent a time period in which ASCs were allowed to expand within the bioreactor; 
throughout days 21-35 ASCs were influenced to differentiate into adipocytes by a medium 
change; adipocytes were maintained from days 35-43.  Glucose consumption is not significantly 
different (p> 0.05, N=3) between groups. 
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Figure 37. Metabolic activity. Lactate production/consumption (mg/hr) trends of three 
bioreactors seeded with ASCs supplemented with a decellularized adipose ECM hydrogel (filled 
squares) and three bioreactors seeded with ASCs only (empty squares) over 43 days of culture.  
Days 0-21 represent a time period in which ASCs were allowed to expand within the bioreactor; 
throughout days 21-35 ASCs were influenced to differentiate into adipocytes by a medium 
change; adipocytes were maintained from days 35-43.  Lactate consumption is mostly not 
significantly different (* p> 0.05, N=3) between groups. 
4.3.3 TNF- α Functional Testing 
Figure 38 depicts the average glucose production of all six bioreactors – three 
each received a decellularized adipose ECM hydrogel upon inoculation (filled squares) 
and three inoculated with ASCs only (empty squares) – before, during, and after insulin 
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stimulation.  Results indicate no significant difference between glucose 
consumption/production of between the groups (p> 0.05, N=3) before, during, and after 
insulin stimulation.   While glucose consumption did slightly decrease during TNF-α 
stimulation, an initial spike in glucose consumption was observed at the beginning of 
insulin stimulation but cells did not seem to recover or return to baseline once stimulated 
with feed medium containing TNF-α and no insulin.  Such results question whether 
mature, functional adipocytes were present within the bioreactor cultures.  
Figure 38. Adipocyte functionality. All six bioreactors were stimulated with TNF-α for twenty-
four hours, glucose consumption was measured and noted to be slightly hindered.  After reaching 
a steady glucose consumption rate, insulin was introduced to the system. Cells inoculated with a 
decellularized adipose ECM hydrogel (filled squares) functions with no significant difference (* p 
< 0.05, N=3) to cells inoculated without a hydrogel (empty squares) when stimulated with TNF-a 
and insulin. 
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4.3.4 Histology and Immunohistochemistry 
Imaging results of the tissue generated within the bioreactors are shown in Figures 
39-41.  Macroscopic tissue formation was observed in and around the hollow fiber
membranes upon bioreactor disassembly [Figs. 38-40].  Regarding both groups of tissue 
– that differentiated from ASCs inoculated in combination with a decellularized adipose
ECM hydrogel and that differentiated from ASCs inoculated with plating medium only – 
histological analyses with Masson’s Trichrome reveal collagen-dense tissue formation, 
with some adipocyte architecture formed (indicated by black arrows in Figure 39).  Lack 
of adipocyte architecture conflicted by observation of metabolic activity from the cultures 
prompted evaluation of a human-specific antibody.  Figure 40 examines the human 
leukocyte antigen (HLA), which should positively stain for human cells only.  While 
some positive stain was observed, the architecture of the samples extracted from the 
bioreactor cultures cannot be identified as similar to that of native human adipose tissue 
(Figure 40A). 
 Confocal fluorescent imaging of AdipoRed was conducted to demonstrate lipid 
formation after 43 days of culture within the dynamic perfusion systems, while DAPI and 
AlexaFluor 488 Phalloidin are meant to highlight nuclei and F-actin, respectively.   
Figure 40 shows some lipid accumulation from the bioreactors inoculated with ASCs and 
decellularized adipose ECM (Fig. 41 A and C) but the only fluorescence from the 
bioreactors withheld from the decellularized adipose ECM (Fig. 41 B and D) is a result 
from potential autofluorescence.  Furthermore, no phalloidin is apparent in any sample, 
indicating no filamentous actin from the tissues grown within the bioreactor cultures. 
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Figure 39. Histology. End-point (43 days) histology stained with Masson’s Trichrome from 
bioreactors inoculated with ASCs and decellularized adipose ECM (A-C) or with ASCs only (D-
F).  Solid arrows indicate adipose architecture, dashed arrows indicate bioreactor fibers. Scale bar 
= 100 μm. 
117 
Figure 40.  HLA Staining.  A) Whole fat from adult human tissue samples, B) sample 
extracted from a bioreactor receiving ASCs + decellularized adipose ECM, C) negative control – 
sample extracted from a bioreactor culture but no primary antibody added to staining procedure, 
D) sample extracted from a bioreactor receiving ASCs and no decellularized adipose ECM. Solid 
arrows indicate adipose architecture, dashed arrows indicate bioreactor fiber. Scale bar = 100 μm. 
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Figure 41. Immunofluorescence. End-point (43 days) AdipoRed/DAPI/Phalloidin 
immunofluorescence from bioreactors containing A and C) ASCs + decellularized adipose ECM 
or B and D) ASCs only.  Scale bar = 100 μm. 
4.4 CONCLUSIONS 
A decellularized adipose ECM biological material was developed, characterized, 
and applied to the hollow fiber-based, three dimensional, dynamic perfusion bioreactor 
culture system described in earlier chapters with the hypothesis that the ECM material 
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would enhance adipogenesis and tissue homogeneity within the bioreactor culture.  
Before bioreactor application, the ECM material was characterized architecturally by 
H&E and SEM, nucleic content was assessed by DAPI staining, and ECM content was 
determined by immunohistochemistry.  Cell viability at 1 and 7 days was evaluated prior 
to bioreactor inoculation.   
Six hollow fiber-based, three dimensional, dynamic perfusion bioreactors were 
inoculated with human adult adipose stem cells, and three were in combination with the 
developed decellularized adipose ECM, three were with ASCs alone.  Cells were allowed 
to expand within the bioreactor cultures for 21 days, then influenced by adipocyte 
differentiation medium for 14 days, then maintained for 7 days.  At the end of the 7-day 
maintenance period, all bioreactors were exposed to TNF-α under the hypothesis that 
mature adipocytes would experience hindered glucose consumption, then recover when 
stimulated with insulin, and return to the baseline glucose levels when the TNF-α is re-
introduced.  Daily glucose and lactate levels in the cultures were measured and, when 
analyzed, consumption rates were averaged, no difference was found between groups in 
the glucose or lactate consumption rates.  Results from the bioreactor experiments 
presented in Specific Aim 3 should be taken with caution as technical difficulties ensued 
throughout experimentation. Such difficulties are further detailed in section 5.2.  
The TNF-α and insulin exposure had little effect on any culture system, 
questioning whether mature adipocytes were achieved in the cultures.  Further supporting 
this assessment is the lack of lactate production within the bioreactor culture systems, 




5.1 SUMMARY OF RESULTS 
ASCs derived from discarded adipose tissue of patients with type II diabetes at 
time of isolation were found to behave metabolically and appear architecturally similar to 
those derived from patients without type II diabetes mellitus when differentiated and 
maintained as adipocytes in the bioreactor system.  When cultured at a physiologically 
relevant glucose level matching that of patients with type II diabetes or without, ASCs 
are able to proliferate, differentiate into adipocytes, and be maintained within the 
bioreactor system.  A decellularized adipose ECM hydrogel was developed and applied 
to the bioreactor cultures; however, based upon the ambiguous results obtained from the 
bioreactor extracted cultures, no conclusion regarding adipocyte differentiation or 
metabolic activity between groups can be made. 
5.1.1  Specific Aim 1 
With obesity rapidly approaching epidemic-status in developed countries, 
followed by type II diabetes mellitus, the need to further understand cellular and 
molecular mechanisms underlying such diseases becomes more apparent.  A key 
influence in these diseases, but still often overlooked as an endocrine-functioning organ, 
is adipose tissue.   Attractive characteristics of adipose tissue make it an appealing source 
of human stem cells for regenerative medicine applications.  Furthermore, purity of ASCs 
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and variance between patients are both well characterized [52, 56, 68]; however, 
traditional, two-dimensional culture of adipose-derived stem cells does not allow long-
term lipid accumulation and, therefore, maintenance of adipocytes [264]. 
Previously, our laboratory has established a three-dimensional perfusion 
bioreactor culture system, providing an environment suitable for long-term maintenance 
of adipocytes within a hollow fiber-based, dynamic mass exchange bioreactor that 
provides decentralized oxygenation [54].  With the intention of serving as a potential tool 
for anti-diabetic drug discovery, Specific Aim 1discusses, to the best of our knowledge – 
for the first time – differentiation of ASCs isolated from diabetic tissue into functional 
adipocytes within a hollow fiber-based, dynamic, three-dimensional perfusion bioreactor.  
The similar metabolic trends observed between diabetic and non-diabetic tissues 
led us to hypothesize that adipose-derived stem cells, once removed from elevated 
glucose and insulin-leveled environments of type II diabetic patients, retain no “memory” 
of the diseased state, confirming insulin/insulin-receptor binding to be environment-
dependent.  While ASCs from diabetic patients consumed less glucose than ASCs from 
non-diabetic patients during the first three weeks of bioreactor culture, results were not 
significantly different (p > 0.05, N=3).  After the “ASC Expansion” period, ASCs were 
exposed to a change in feed media – to induce differentiation into adipocytes – during 
this phase and the “adipocyte maintenance” phase, glucose consumption was expected to 
not increase, indicating differentiation and maintenance rather than ASC proliferation.  
To evaluate adipocyte functionality within the bioreactor of both tissue types (diabetic 
and non-diabetic), after exposure to TNF-α, insulin was introduced to all bioreactors and 
glucose uptake was observed to increase over an eight-hour period and eventually return 
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to the inhibited TNF-α level.  Throughout insulin stimulation, three statistically 
significant time points were observed between the diabetic and non-diabetic groups (p < 
0.05, N=3), indicating that adipocytes from diabetic patients may not recover with insulin 
as functionally as adipocytes from non-diabetic patients.  While the dissimilarity is small, 
the disparity in glucose consumption may reflect the ability of tissue from diabetic ASCs 
to recover after 24 hours of inhibited glucose uptake [169, 264].    However, after the 8 
hours of insulin stimulation, glucose consumption was inhibited to the same degree 
between the two groups (p > 0.05, N=3).  
While the cells studied within this report are derived from different patients 
within the two experimental groups, previous work in our laboratory has been conducted 
establishing ASCs obtained from different patients within certain age and BMI ranges 
hold inconsequential differences between proliferation and differentiation capabilities 
[52].  No prominent, qualitative difference was noted between architecture or formation, 
of adipocytes differentiated from diabetic versus non-diabetic ASCs when cultured and 
differentiated in the hollow fiber bioreactors for 45 days.  When stained with AdipoRed, 
DAPI and Phalloidin AlexaFluor 488, lipid-loaded vacuoles indicate mature adipose 
tissue upon the extracted hollow membrane fibers from all bioreactors, including those 
inoculated with cells from diabetic patients [Figs. 9 and 10].  In Figure 10, the Phalloidin 
indicates a less organized lipid-storing tissue from the bioreactors seeded with ASCs 
from diabetic patients.  No quantitative variance was detected of adipocyte gene marker, 
FABP4, expressed between adipocytes differentiated from diabetic patients, non-diabetic 
patients, and whole adipose tissue samples [Fig. 12].  PPAR-γ protein expression 
exhibited through Western Blotting was confirmed from diabetic and non-diabetic 
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bioreactor samples and whole adipose samples.Protein band strength in the Western 
Blotting is not equal between groups and samples extracted for Western Blotting were 
taken at random from the bioreactors.  
It can be concluded from Specific Aim 1 that ASC proliferation, differentiation 
and maintenance is dependent on microenvironment and, when placed at the same culture 
conditions, ASCs from patients with type II diabetes mellitus will behave similarly to 
ASCs from patients without type II diabetes long-term in three dimensions ex vivo.  
These conclusions hold promise for future clinical applications such as ASC therapy 
addressing diabetic wounds. 
5.1.2  Specific Aim 2 
Based on the conclusions formed in Specific Aim 1, it is clear that, in order to 
study type II diabetes long-term ex vivo, a physiologically relevant culture condition must 
be engineered.  Since the traditional culture medium used in ASC culture contains a 
glucose concentration 3-4 times greater than that observed in healthy fasting adults and 2-
3 times higher than that observed in patients with type II diabetes mellitus, further 
investigation of ASC behavior under the influence of feed medium containing 
physiological glucose levels is essential.  
In 96 well plates, ASCs were seeded and cultured by feed medium at various 
glucose concentrations.  Differentiation and cell viability was assessed in addition to cell 
behavior once exposed to various environments similar to that of a patient with type II 
diabetes mellitus.  A 20% and 35% dilution of adipocyte differentiation medium were 
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found to be the most physiologically relevant to glucose concentrations of patients 
without and with type II diabetes mellitus, respectively.  Free fatty acids (FFAs) and the 
sphingolipid, C2-ceramide, were added to adipocyte culture media and glucose 
consumptions was hindered the most ideally at a concentration of 10 μM C2-ceramide 
without FFAs. 
The established culture conditions were applied to the hollow fiber-based, three-
dimensional dynamic perfusion bioreactor system.  ASCs were able to proliferate, 
differentiate, and be maintained in both culture conditions.  However, when C2-ceramide 
was added to the healthy glucose concentration cultures, no major change in glucose 
consumption was experienced.  A potential rationale for this observation may be due to a 
scale-up issue; two-dimensional experiments in the 96 well plates were applied to 10,000 
cells per well, whereas ASCs are inoculated into the bioreactors at 80,000,000 cells per 
reactor.  Another possibility may lie within the maturity level of the adipocytes; the 
glucose consumption hindered by C2-ceramide in the 96 well plate experiments were of 
adipocytes immediately post-differentiation, and the C2-ceramide was included in the 
bioreactor studies after a week of maintenance to mature adipocytes in three dimensions. 
5.1.3 Specific Aim 3 
To further enhance adipogenesis and to promote adipose tissue homogeneity 
within the bioreactor cultures, a decellularized adipose ECM hydrogel was developed 
using modified methods of previous literature [261, 263].  The adipose ECM was 
characterized by H&E, SEM, DAPI, immunohistochemistry, and cell viability through 
Live/Dead.  The developed adipose ECM was found to have no lipid architecture, no 
125 
notable nuclei, a porous surface, and retained several important ECM components such as 
collagens I, III, IV, VI, heparan sulfate proteoglycans (HSPG), and nidogen. 
 When ASCs were seeded onto the adipose ECM, at 24 hours, a significant 
increase was observed in live cells from groups without the adipose ECM compared to 
the groups of cells seeded onto the adipose ECM.  However, after a week of culture, no 
difference in live cells was found.  The decellularized adipose ECM was able to form a 
hydrogel following pepsin digestion and at 37 °C.  The hydrogel was combined with 
ASCs and inoculated into three of the six bioreactors; the other three bioreactors received 
ASCs only.   All cultures were expanded for 21 days, then exposed to adipocyte 
differentiation feed medium for 14 days, and maintained for 7 days.  Following 
maintenance, TNF-α followed by insulin were introduced to the system to test the 
functionality of the tissue within the bioreactors.   
Addition of the decellularized adipose ECM did not have a statistically significant 
effect on glucose or lactate production rates of the ASCs and, while AdipoRed indicated 
slight lipid inclusion, the adipose ECM incorporation did not enhance adipogenesis and 
mature adipocytes were not found within any of the six bioreactor cultures.  However, 
this final experiment was fraught with technical difficulties as indicated by the lack of 
lactate production within the bioreactor culture systems, uniocular adipocytes, lipid 
accumulation, and F-actin revealed in the AdipoRed immunofluorescence. 
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5.2 TECHNICAL CONSIDERATIONS 
Three-dimensional perfusion technology, such as that described throughout this 
dissertation is more technical than traditional Petri dish or two-dimensional tissue culture 
flask culture.  The three-dimensional bioreactors used in this dissertation involved pumps 
and continuous media exchange through a dynamic system, which is constantly under 
perfusion where pressure problems may occur.  Opposed to traditional two-dimensional 
cell culture that involves daily pipetting, three-dimensional perfusion utilizes an input of 
constant nutrient medium with continuous output of waste.  If a bottle of nutrient medium 
becomes empty, or the liquid volume falls below the reach of the straw drawing the 
medium into the bioreactors, air bubbles will occur in the system.  Air bubbles within the 
system could cause membrane fouling, premature closing of the capillaries and pressure 
buildup.  If not monitored closely, this would lead to an automatic shut down of the pump 
system. 
During the experiments described in Specific Aim 3, a phenomenon such as this 
occurred more than once, including automatic shut down of the pump system.  The 
pumps were restarted and, if necessary, the bioreactor systems were transferred to a 
different set of pumps.  Nutrient media run empty if fresh media bottles are not delivered 
or replaced in time, or if the system pumps at a faster rate.  The system may pump too 
quickly if the pressure on the tubing is lowered caused by an incorrect setup of race 
sizing on the pumps.   
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Furthermore, at the time of cell inoculation into the bioreactors, all stopcocks 
must be in proper position, otherwise air would occur in the system.   Another 
consequence of air in the system is that cells could dry out.  While oxygenation keeps the 
cells alive within the compartment, but automatic shut down of the pumps would result in 
no CO2, leading to acidic buildup in the system.  All of the mentioned technical 
challenges could be avoided by a careful setup and by potential implementation of a 
camera system to allow constant monitoring of the systems after hours.  
Another classification of technical challenges that may have potentially occurred 
in Specific Aim 3 would be a bacterial infection.  The bioreactor systems are highly 
sensitive and extremely vulnerable to infection throughout all experimentation.  Bacterial 
infection would continue to consume glucose, as observed in Specific Aim 3.  
Throughout experimentation, white, flaky debris were found in the bubble traps and 
waste containers of all bioreactors, including those not inoculated with a decellularized 
hydrogel.  Unfortunately, the debris was unable to be analyzed as the texture would 
adhere to the inside of the bubble trap and disintegrated during processing.  
5.3 FUTURE DIRECTIONS 
Diabetes mellitus and obesity exist as rapidly increasing issues in developed 
countries, a deeper understanding of adipose tissue as an endocrine organ is necessary.  
The application of autologous adipose stem cell therapy to patients with type II diabetes 
before, during, and after the disease is a pressing issue that holds serious potential to 
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many fields including regenerative medicine, plastic surgery and reconstruction, 
endocrinology, and diabetic wound healing.  Future directions include optimizing 
medium components, clinical application of the decellularized adipose hydrogel to soft 
tissue reconstruction and graft volume retention, engineering a long-term diabetic model 
of adipocytes in a bioreactor, and utilizing the model as a drug discovery tool for various 
factors addressing diabetes, obesity, and adipose graft volume retention. 
Due to the limitations of the presented studies and technical difficulties 
encountered, further studies must be completed before the aforementioned future 
directions may be obtained.  For such studies, considering the experience in the described 
current work, the following suggestions are given. 
Specific Aim 1. To continue development of a long-term culture environment that 
mimics II diabetes mellitus ex vivo. 
Hypothesis: Addition of macrophages M1 and M2 into the culture will create insulin 
resistance of adipocytes within a hollow fiber-based, three-dimensional dynamic 
perfusion bioreactor. 
Rationale: The studies described in Specific Aim 2 were designed to create an 
environment representative of type II diabetes mellitus via glucose uptake hindrance 
influenced by exposure to FFAs and C2-ceramide in the culture medium.  However, no 
notable difference was observed within the adipocyte cultures ex vivo.  Obesity and type 
II diabetes are both characterized by adipose tissue macrophages (ATMs) and ATMs are 
accepted correlations to adipose tissue insulin resistance [264, 265].   
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Specific Aim 2. To further discover adipose-derived stem cells from patients with type II 
diabetes mellitus within a diabetic environment ex vivo. 
Hypothesis: ASCs isolated from tissue of patients with type II diabetes mellitus 
influenced by a decellularized adipose extracellular matrix isolated from patients with 
type II diabetes mellitus will exhibit less glucose uptake, proliferation, and differentiation 
capabilities than ASCs isolated from tissue of healthy patients influenced by a 
decellularized adipose ECM from healthy patients. 
Rationale.  Specific Aim 1 within the presented thesis supports adipose tissue behavior 
within a three-dimensional dynamic perfusion bioreactor relying upon the surrounding 
microenvironment.  While the cellular components of the incorporated matrix will have 
been removed, the ECM is expected to contain less structural proteins such as collagen I, 
III, IV, VI, nidogen, or HSPG that contribute to cellular organization, migration, and 
proliferation.  
Specific Aim 3. To enhance adipogenesis and encourage neovascularization within a 
hollow fiber-based, three-dimensional dynamic perfusion bioreactor. 
Hypothesis: Exposure of platelet-rich plasma (PRP) to healthy ASCs will enhance 
adipogenesis and encourage clinical usage for wound healing application. 
Rationale.  Clinical evidence has supported the addition of PRP to autologous fat graft 
transplantations to improve fat-graft survival by influencing differentiation of pre-
adipocyte cells contained the graft tissue [264-275].  
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